"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,WO,A1,WO 1997/002115 A1,116-553-122-725-656,1997-01-23,1997,US 9610975 W,1996-06-27,US 49702195 A,1995-06-30,A TRAIL BLAZING STUMPCUTTER,"The grass and tree stumpcutter consists of a circular top plate (1) made of ALMAG 35 with a center hole (2) and three through-holes (3, 4, 5) near its rim and 120 degrees apart from one another into which three cylindrically-shaped pins (6, 7, 8) have been tightly pressed. Three identical beveled metallic blades (9, 10, 11) with rounded holes (9A, 10A, 11A) in them are swivably received one each by pins (6, 7, 8). A circular bottom plate (20), also made of ALMAG 35, has a center hole (21) and three broken holes for receipt of the bottoms of pins (6, 7, 8) when the stump cutter is fully assembled plate-to-plate, via the center holes and adapter means (29), to the rotary head of a motorized grass cutter.",GROSSI EDWARD J,GROSSI EDWARD J;;TAGGETT PETER T,,https://lens.org/116-553-122-725-656,Patent Application,yes,10,3,3,3,0,A01D34/736;;A01D34/90;;A01G3/08;;A01G23/067;;A01G3/08;;A01D34/736;;A01D34/90;;A01G23/067,A01D34/73;;A01D34/90;;A01G3/08;;A01G23/06,,0,0,,,,PENDING
2,AU,A,AU 1996/064792 A,170-935-758-247-68X,1997-02-05,1997,AU 1996/064792 A,1996-06-27,US 49702195 A;;US 9610975 W,1995-06-30,A trail blazing stumpcutter,,EDWARD J GROSSI,GROSSI EDWARD J;;TAGGETT PETER T,,https://lens.org/170-935-758-247-68X,Patent Application,no,0,0,3,3,0,A01D34/736;;A01D34/90;;A01G3/08;;A01G23/067;;A01G3/08;;A01D34/736;;A01D34/90;;A01G23/067,A01D34/73;;A01D34/90;;A01G3/08;;A01G23/06,,0,0,,,,PENDING
3,US,S,US D0370489 S,012-882-478-223-119,1996-06-04,1996,US 4020195 F,1995-06-05,US 4020195 F,1995-06-05,Rotatory brush cutting tool top plate,,TAGGETT PETER T;;GROSSI EDWARD J,TAGGETT PETER T;;GROSSI EDWARD J,TUFF-KUTT INC (1995-06-13),https://lens.org/012-882-478-223-119,Design Right,yes,3,15,1,1,0,,,D15/17,0,0,,,,EXPIRED
4,US,A,US 5617636 A,082-366-014-908-580,1997-04-08,1997,US 49702195 A,1995-06-30,US 49702195 A,1995-06-30,Trail blazing stumpcutter,The instant device consists of a circular top plate made of ALMAG 35 aluminum and magnesium alloy material with a centerhole and three through holes near its rim and 120.degree. apart from one another into which three cylindrically shaped pins have been tightly pressed. Three identical beveled metallic blades with rounded holes in them are swivably received one each by the pins. A circular bottom plate also made of such ALMAG 35 material has a centerhole and three broken holes for receipt of the bottoms of the pins when the device is fully assembled plate to plate and held with a bolt and nut from below the bottom plate via the centerholes and adapter means to the rotatory head of a motorized brush cutting unit. A centrally located elevation upward in the bottom plate co-extensive with two convex ridges on its top surface fits into a centrally positioned cylindrical well in the bottom side of the top plate co-extensive with two concave depressions in the wall of the well as the depressions concomitantly receive the ridges thereby sandwiching the blades and pins during completed assembly of the invention to the rotatory head. A left handed nut serves to secure the fully assembled invention intact and the nut is self tightening during counterclockwise head rotation.,TAGGETT; PETER T.;;GROSSI; EDWARD J.,TAGGETT PETER T;;GROSSI EDWARD J,TUFF-KUTT INC (1995-06-08),https://lens.org/082-366-014-908-580,Granted Patent,yes,9,67,3,3,0,A01D34/736;;A01D34/90;;A01G3/08;;A01G23/067;;A01G3/08;;A01D34/736;;A01D34/90;;A01G23/067,A01D34/73;;A01D34/90;;A01G3/08;;A01G23/06,30/276;;30/347;;56/12.7,0,0,,,,EXPIRED
5,CN,A,CN 116059313 A,082-140-899-051-235,2023-05-05,2023,CN 202211345357 A,2018-04-09,US 201762483295 P;;US 201762485343 P;;CN 201880037570 A;;US 2018/0026753 W,2017-04-07,Dosing regimens and related compositions and methods,"In certain aspects, the present invention provides cell reactive compstatin analogs and compositions comprising cell reactive compstatin analogs. In certain aspects, the invention further provides methods of using the cell reactive compstatin analogs, for example, to treat complement-mediated disorders, for example, to inhibit complement-mediated damage to a cell, tissue, or organ. In certain aspects, the present invention provides long acting compstatin analogs and compositions comprising long acting compstatin analogs. In certain aspects, the invention further provides methods of using the long-acting compstatin analogs, e.g., for treating complement-mediated conditions, e.g., for inhibiting complement-mediated damage to cells, tissues, or organs. In certain aspects, the present invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In certain aspects, the invention further provides methods of using targeted compstatin analogs, e.g., for treating complement-mediated disorders, e.g., for inhibiting complement-mediated damage to cells, tissues, or organs.",APELLIS PHARMACEUTICALS INC,GROSSI FEDERICO;;DESCHATELETS PASCAL;;FRANCOIS CEDRIC;;JOHNSON PETER;;VEGA CARLOS,,https://lens.org/082-140-899-051-235,Patent Application,no,0,0,20,20,0,A61K38/12;;A61K47/60;;A61K9/0021;;A61P7/06;;A61P13/12;;A61P21/00;;A61P25/00;;A61P9/00;;A61P13/00;;A61M5/1452;;A61K38/00;;C07K7/08;;A61P27/02;;A61P37/06;;A61P7/00;;A61P7/06;;A61P9/10;;A61K47/60;;A61K47/643;;C07K7/08;;A61K9/0019;;A61K9/0021;;A61K9/0048;;A61P7/06;;A61P9/10;;A61P27/02;;A61P37/06;;A61K38/00;;A61K47/643;;A61K47/6901;;A61K47/60;;A61P7/00;;A61P37/06;;A01N1/0226;;A61K9/0019;;A61K38/00;;A61M5/14248;;A61M5/1452;;A61M5/152;;C07K7/08,A61K38/12;;A61K9/00;;A61K47/60;;A61M5/145;;A61P7/06;;A61P9/00;;A61P13/00;;A61P13/12;;A61P21/00;;A61P25/00,,0,0,,,,PENDING
6,US,A1,US 2009/0100498 A1,142-720-439-289-328,2009-04-16,2009,US 87137407 A,2007-10-12,US 87137407 A,2007-10-12,METHOD AND SYSTEM FOR ANALYZING POLICIES FOR COMPLIANCE WITH A SPECIFIED POLICY USING A POLICY TEMPLATE,"A method and system are disclosed for analyzing policies for compliance with a specified policy. The method comprises the steps of creating a policy template representing said specified policy, and comparing a group of given policies to said policy template to determine whether said given policies conflict with said specified policy. In the preferred embodiment of the invention, the specified policy may include specified rules, the given policies include a plurality of given rules, and the policy template expresses said specified rules. In this preferred embodiment, the comparing step includes the step of comparing said plurality of given rules to the policy template to determine whether any of said given rules conflicts with said specified rules. In addition, preferably, if conflicts are found between said given policies and said specified policy, the given policies are modified to eliminate the conflicts.",IBM,GROSSI ALDO P;;KARAT CLAIRE-MARIE N;;MALKIN PETER K;;ZUNIC NEVENKO,INTERNATIONAL BUSINESS MACHINES CORPORATION (2007-10-10),https://lens.org/142-720-439-289-328,Patent Application,yes,13,16,2,2,0,G06Q10/10;;G06Q10/10,G06F17/00,726/1,2,1,007-352-001-015-794,10.1109/re.2011.6051661,"IEEE-SA Standards Board, ""Draft Standard Policy Language Requirements and System Architectures for Dynamic Spectrum Access Systems"", 2011, IEEE, pgs. 1-60;;Massey, ""Assessing the Accuracy of Legal Implementation Readiness Decisions"", 2011, IEEE, pg. 207-216",INACTIVE
7,US,B2,US 8793781 B2,000-345-098-250-394,2014-07-29,2014,US 87137407 A,2007-10-12,US 87137407 A,2007-10-12,Method and system for analyzing policies for compliance with a specified policy using a policy template,"A method and system are disclosed for analyzing policies for compliance with a specified policy. The method comprises the steps of creating a policy template representing said specified policy, and comparing a group of given policies to said policy template to determine whether said given policies conflict with said specified policy. In the preferred embodiment of the invention, the specified policy may include specified rules, the given policies include a plurality of given rules, and the policy template expresses said specified rules. In this preferred embodiment, the comparing step includes the step of comparing said plurality of given rules to the policy template to determine whether any of said given rules conflicts with said specified rules. In addition, preferably, if conflicts are found between said given policies and said specified policy, the given policies are modified to eliminate the conflicts.",GROSSI ALDO P;;KARAT CLAIRE-MARIE N;;MALKIN PETER K;;ZUNIC NEVENKO;;IBM,GROSSI ALDO P;;KARAT CLAIRE-MARIE N;;MALKIN PETER K;;ZUNIC NEVENKO,INTERNATIONAL BUSINESS MACHINES CORPORATION (2007-10-10),https://lens.org/000-345-098-250-394,Granted Patent,yes,13,163,2,2,0,G06Q10/10;;G06Q10/10,G06F21/00,726/10;;719/318;;379/220.01,4,3,007-352-001-015-794;;088-082-461-023-374;;137-400-085-804-64X,10.1109/re.2011.6051661;;10.1145/1124772.1124787;;10.1145/1143120.1143123,"IEEE-SA Standards Board, ""Draft Standard Policy Language Requirements and System Architectures for Dynamic Spectrum Access Systems"", 2011, IEEE, pp. 1-60.;;Massey, ""Assessing the Accuracy of Legal Implementation Readiness Decisions"", 2011, IEEE, p. 207-216.;;Karat, et al., ""Evaluating Interfaces for Privacy Policy Rule Authoring"", Proceedings of the SIGCHI Conference on Human Factors in Computing Systems, CHI '06, Apr. 22-27, 2006; and.;;Brodie, et al, An Empirical Study of Natural Language Parsing of Privacy Policy Rules Using the SPARCLE Policy Workbench The SPARCLE Policy Workbench (2006).",INACTIVE
8,CN,A,CN 115675109 A,026-629-669-963-645,2023-02-03,2023,CN 202210083006 A,2022-01-25,US 202117443525 A,2021-07-27,System and method for electric vehicle speed control,"The invention relates to a system and method for electric vehicle speed control. Exemplary methods and systems for controlling a speed of a vehicle may generally use an autonomous control module of the vehicle to determine a target vehicle acceleration. The target vehicle acceleration may be determined based on at least one of a target vehicle following distance, a target vehicle following speed, or a target vehicle speed. Using a vehicle dynamics module of the vehicle, the determined vehicle acceleration may be mapped to the vehicle torque level. In addition, the vehicle torque level may be applied to one or more wheels of the vehicle.",RIVIAN IP HOLDINGS LLC,GROSSI GARY J;;THEODOSIS PETER;;GURASUBRAMANIAN SRINIVAS;;HAAR THOMAS;;WADDELL NICK;;HELLMERS MICHAEL,,https://lens.org/026-629-669-963-645,Patent Application,no,0,0,3,3,0,B60W2554/802;;B60W2554/4042;;B60W2520/10;;B60W2720/106;;B60W2720/30;;B60W2552/15;;B60W2530/16;;B60W30/16;;B60W2530/10;;B60W30/143;;B60W30/16;;B60W30/18127;;B60W40/105;;B60W40/1005;;B60W2720/30;;B60W10/18;;B60W2520/105;;B60W2554/802;;B60W2554/804;;B60W40/06,B60L15/20,,0,0,,,,PENDING
9,US,A1,US 2023/0126764 A1,062-336-226-683-624,2023-04-27,2023,US 202117507388 A,2021-10-21,US 202117507388 A,2021-10-21,MIXED QUANTUM-CLASSICAL METHOD FOR FRAUD DETECTION WITH QUANTUM FEATURE SELECTION,"A computer-implemented system, platform, method and computer program product for optimizing a data analytics fraud prediction/detection pipeline that includes a combination of a classical machine learned classifier model with a quantum machine learned model to optimize the performance of the fraud prevention model. The feature selection uses different feature maps: one determined by the classic classifier and the other determined by the quantum model implementation that exploits the entanglement quantum property. The quantum method can include a quantum support vector machine implementing a built feature forward algorithm that uses a quantum kernel estimate for feature mapping. This quantum model can be run on a quantum computer or quantum simulator that can run a quantum algorithm built for extracting feature importance. A decision classifier is further developed to decide which model output prediction is more correct in the instance there is a disagreement in each of the ensemble model’s activity determination.",IBM,IBRAHIM NOEL R;;RADESCU VOICA ANA MARIA;;GROSSI MICHELE;;VON ALTROCK CONSTANTIN HARALD PETER;;MUENTNER KIRSTEN,INTERNATIONAL BUSINESS MACHINES CORPORATION (2021-10-21),https://lens.org/062-336-226-683-624,Patent Application,yes,16,3,2,2,0,G06Q20/4016;;G06N10/60;;G06Q20/389;;G06N20/10;;G06N10/40;;G06N20/10;;G06N10/20;;G06N10/60;;G06Q20/4016,G06Q20/40;;G06N10/20;;G06N10/60;;G06N20/10,,6,2,057-422-754-412-684;;105-913-088-504-258,10.1109/qce52317.2021.00083;;10.1109/icdim.2018.8847063,"Pistoia, Marco et al, ""Quantum Machine Learning for Finance,"", Future Lab for Applied Research and Engineering, J.P. Morgan Chase Bank, N.A. September 9th, 2021, pages 1-11. (Year: 2021);;Orus, Roman et al, ""Quantum computing for finance: Overview and prospects"", Reviews in Physics, February 12th, 2019, pages 1-12. (Year: 2019);;S. Mitra and K. Rao JV, ""Experiments on Fraud Detection use case with QML and TDA Mapper,"" 2021 IEEE International Conference on Quantum Computing and Engineering (QCE), Broomfield, CO, USA, 2021, pp. 471-472. (Year: 2021);;A. E. Bouchti, Y. Tribis, T. Nahhal and C. Okar, ""Forecasting Financial Risk using Quantum Neural Networks,"" 2018 Thirteenth International Conference on Digital Information Management (ICDIM), Berlin, Germany, 2018, pp. 386-390. (Year: 2018);;Pistoia, Marco et al, ""Quantum Machine Learning for Finance,"", Future Lab for Applied Research and Engineering ,J.P. Morgan ChaseBank,N.A.September9th,2021,pages1-11. (Year: 2021);;Orus, Roman et al, ""Quantum computing for finance: Overview and prospects"", Reviews in Physics, February12th, 2019, pages1- 12.(Year:2019) (Year: 2019)",PENDING
10,HU,T2,HU E035931 T2,156-229-915-208-911,2018-06-28,2018,HU E09789125 A,2009-08-13,US 14616309 P;;US 8880108 P;;US 18334509 P;;US 8870408 P;;US 9009608 P;;US 18152709 P,2008-08-13,"PHARMACEUTICAL COMPOSITION OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4- OXOQUINOLINE-3-CARBOXAMIDE AND ADMINISTRATION THEREOF",,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS;;OVERHOFF KIRK;;GROOTENHUIS PETER;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/156-229-915-208-911,Amended Patent,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K47/32;;A61K9/16;;A61K9/20;;A61K9/28;;A61K31/47,,0,0,,,,PENDING
11,ES,T3,ES 2660143 T3,140-551-965-210-328,2018-03-21,2018,ES 09789125 T,2009-08-13,US 14616309 P;;US 8880108 P;;US 18334509 P;;US 8870408 P;;US 9009608 P;;US 18152709 P;;US 2009/0004629 W,2008-08-13,"Composición farmacéutica de N-[2,4-Bis(1,1-dimetiletilo)-5-hidroxifenilo]-1,4-dihidro-4-oxoquinolina-3carboxamida y administración de la misma","Una composición farmacéutica en forma de comprimido que comprende a. 34,1% en peso de una dispersión sólida en peso de la composición, en el que la dispersión comprende 80% en peso de N-[2,4-Bis(1,1-dimetiletilo)-5-hidroxifenilo]-1,4-dihidro-4-oxoquinolina-3-carboxamida sustancialmente amorfa (Compuesto 1) en peso de la dispersión, 19,5% en peso de HPMCAS en peso de la dispersión, y 0,5% en peso de SLS en peso de la dispersión; b. 30,5% en peso de celulosa microcristalina en peso de la composición; c. 30,4% en peso de lactosa en peso de la composición; d. 3% en peso de croscarmelosa sódica en peso de la composición; e. 0,5% en peso de SLS en peso de la composición; f. 0,5% en peso de dióxido de silicio coloidal en peso de la composición; y g. 1,0% en peso de estearato de magnesio en peso de la composición.",VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS;;OVERHOFF KIRK;;GROOTENHUIS PETER;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/140-551-965-210-328,Granted Patent,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K47/32;;A61K9/16;;A61K9/20;;A61K9/28;;A61K31/47,,0,0,,,,ACTIVE
12,MX,A,MX 2011001782 A,170-955-227-965-98X,2012-02-08,2012,MX 2011001782 A,2009-08-13,US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P;;US 2009/0004629 W,2008-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF.,"The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-ox oquinoline- 3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.",VERTEX PHARMA,YOUNG CHRISTOPHER;;GROSSI ALFREDO;;ROWE WILLIAM;;HURTER PATRICIA;;DINEHART KIRK;;OVERHOFF KIRK;;GROOTENHUIS PETER D;;BOTFIELD MARTYN;;VERWIJS MARINUS JACOBUS,,https://lens.org/170-955-227-965-98X,Patent Application,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K47/32,,0,0,,,,PENDING
13,HR,T1,HR P20210208 T1,136-589-491-942-840,2021-03-19,2021,HR P20210208 T,2021-02-05,US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P;;EP 17204189 A,2008-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF,,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/136-589-491-942-840,Granted Patent,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K9/16;;A61K9/20;;A61K9/28;;A61K31/47,,0,0,,,,ACTIVE
14,EP,A2,EP 2328618 A2,171-360-556-485-42X,2011-06-08,2011,EP 09789125 A,2009-08-13,US 2009/0004629 W;;US 14616309 P;;US 8880108 P;;US 18334509 P;;US 8870408 P;;US 9009608 P;;US 18152709 P,2008-08-13,"PHARMACEUTICAL COMPOSITION OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4- OXOQUINOLINE-3-CARBOXAMIDE AND ADMINISTRATION THEREOF",,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,VERTEX PHARMACEUTICALS INC. (2014-02-26);;VERTEX PHARMACEUTICALS INCORPORATED (2014-08-27),https://lens.org/171-360-556-485-42X,Patent Application,yes,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K47/32;;A61K9/16;;A61K9/20;;A61K9/28;;A61K31/47,,0,0,,,,ACTIVE
15,WO,A3,WO 2010/019239 A3,109-703-909-131-533,2011-05-26,2011,US 2009/0004629 W,2009-08-13,US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P,2008-08-13,"PHARMACEUTICAL COMPOSITION OF N- [2,4-BIS (1, 1 -DIMETHYLETHYL) - 5 - HYDROXYPHENYL] - 1, 4 - DIHYDRO - 4 - OXOQUINOLINE - 3 - CARBOXAMIDE AND ADMINISTRATION THEREOF","The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline- 3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.",VERTEX PHARMA;;ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/109-703-909-131-533,Search Report,yes,1,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K47/32,,0,0,,,,PENDING
16,US,A1,US 2014/0112988 A1,009-255-811-316-140,2014-04-24,2014,US 201314135323 A,2013-12-19,US 201314135323 A;;US 58306609 A;;US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P,2008-08-13,Pharmaceutical Composition and Administrations Thereof,"The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.",VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,VERTEX PHARMACEUTICALS INCORPORATED (2010-07-28),https://lens.org/009-255-811-316-140,Patent Application,yes,0,45,33,98,0,A61K9/1635;;A61K9/1652;;A61K9/282;;A61K31/44;;A61K9/2054;;A61K31/47;;A61P11/00;;A61P11/08;;A61P19/00;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/00;;A61P43/00;;A61K31/47;;A61K9/14;;A61K9/1635;;A61K9/282;;A61K9/1652;;A61K31/44;;A61K9/2054;;A61K31/47;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2027;;A61K9/284;;A61K9/0053;;A61K9/28,A61K9/28;;A61K9/20;;A61K31/47,424/467;;514/312;;424/489;;424/475;;424/476,0,0,,,,DISCONTINUED
17,CN,A,CN 102231990 A,025-629-966-236-210,2011-11-02,2011,CN 200980135449 A,2009-08-13,US 2009/0004629 W;;US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P,2008-08-13,"Pharmaceutical composition of n- [2, 4-bis (1, 1-dimethylethyl)-5- hydroxyphenyl]- 1, 4 -dihydro-4-oxoquinoline-3- carboxamide and administration thereof","The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2, 4-Bis(1, 1-dimethylethyl)-5-hydroxyphenyl]-1, 4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.",VERTEX PHARMA,WILLIAM ROWE;;PATRICIA HURTER;;CHRISTOPHER YOUNG;;KIRK DINEHART;;JACOBUS VERWIJS MARINUS;;KIRK OVERHOFF;;GROOTENHUIS PETER D J;;MARTYN BOTFIELD;;ALFREDO GROSSI,,https://lens.org/025-629-966-236-210,Patent Application,no,0,11,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K47/32,,0,0,,,,ACTIVE
18,HK,A1,HK 1161140 A1,042-844-150-472-921,2012-08-24,2012,HK 12102076 A,2012-02-29,US 2009/0004629 W;;US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P,2008-08-13,HK 1161140 A1,,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/042-844-150-472-921,Patent Application,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K/,,0,0,,,,PENDING
19,PT,T,PT 2328618 T,091-331-171-943-415,2018-03-05,2018,PT 09789125 T,2009-08-13,US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P,2008-08-13,"PHARMACEUTICAL COMPOSITION OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4- OXOQUINOLINE-3-CARBOXAMIDE AND ADMINISTRATION THEREOF",,VERTEX PHARMA,PATRICIA HURTER;;WILLIAM ROWE;;PETER D J GROOTENHUIS;;CHRISTOPHER YOUNG;;KIRK DINEHART;;MARINUS JACOBUS VERWIJS;;KIRK OVERHOFF;;MARTYN BOTFIELD;;ALFREDO GROSSI,,https://lens.org/091-331-171-943-415,Patent Application,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K47/32;;A61K9/16;;A61K9/20;;A61K9/28;;A61K31/47,,0,0,,,,PENDING
20,LT,T,LT 3345625 T,155-251-501-345-646,2021-02-10,2021,LT 17204189 T,2009-08-13,US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P,2008-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF,,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/155-251-501-345-646,Unknown,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K9/16;;A61K9/20;;A61K9/28;;A61K31/47,,0,0,,,,PENDING
21,HR,T1,HR P20180328 T1,196-829-627-836-18X,2018-04-20,2018,HR P20180328 T,2018-02-22,US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P;;EP 09789125 A;;US 2009/0004629 W,2008-08-13,"PHARMACEUTICAL COMPOSITION OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4- OXOQUINOLINE-3-CARBOXAMIDE AND ADMINISTRATION THEREOF",,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/196-829-627-836-18X,Granted Patent,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K47/32;;A61K9/16;;A61K9/20;;A61K9/28;;A61K31/47,,0,0,,,,ACTIVE
22,PL,T3,PL 2328618 T3,179-143-981-047-594,2018-06-29,2018,PL 09789125 T,2009-08-13,US 14616309 P;;US 8880108 P;;US 18334509 P;;US 8870408 P;;US 9009608 P;;US 18152709 P;;EP 09789125 A;;US 2009/0004629 W,2008-08-13,"PHARMACEUTICAL COMPOSITION OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4- OXOQUINOLINE-3-CARBOXAMIDE AND ADMINISTRATION THEREOF",,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/179-143-981-047-594,Patent Application,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K47/32;;A61K9/16;;A61K9/20;;A61K9/28;;A61K31/47,,0,0,,,,PENDING
23,EP,B1,EP 2328618 B1,118-728-143-617-659,2017-11-29,2017,EP 09789125 A,2009-08-13,US 2009/0004629 W;;US 14616309 P;;US 8880108 P;;US 18334509 P;;US 8870408 P;;US 9009608 P;;US 18152709 P,2008-08-13,"PHARMACEUTICAL COMPOSITION OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4- OXOQUINOLINE-3-CARBOXAMIDE AND ADMINISTRATION THEREOF",,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,VERTEX PHARMACEUTICALS INC. (2014-02-26);;VERTEX PHARMACEUTICALS INCORPORATED (2014-08-27),https://lens.org/118-728-143-617-659,Granted Patent,yes,1,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K47/32;;A61K9/16;;A61K9/20;;A61K9/28;;A61K31/47,,0,0,,,,ACTIVE
24,CA,A1,CA 2733908 A1,164-565-880-043-442,2010-02-18,2010,CA 2733908 A,2009-08-13,US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P;;US 2009/0004629 W,2008-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF,"The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline- 3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.",VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/164-565-880-043-442,Patent Application,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K47/32,,0,0,,,,ACTIVE
25,US,A1,US 2021/0023070 A1,029-426-713-966-931,2021-01-28,2021,US 202016842480 A,2020-04-07,US 202016842480 A;;US 201615253636 A;;US 201314135323 A;;US 58306609 A;;US 18334509 P;;US 18152709 P;;US 14616309 P;;US 9009608 P;;US 8880108 P;;US 8870408 P,2008-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF,"The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.",VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,VERTEX PHARMACEUTICALS INCORPORATED (2010-07-28),https://lens.org/029-426-713-966-931,Patent Application,yes,0,6,33,98,0,A61K9/1635;;A61K9/1652;;A61K9/282;;A61K31/44;;A61K9/2054;;A61K31/47;;A61P11/00;;A61P11/08;;A61P19/00;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/00;;A61P43/00;;A61K31/47;;A61K9/14;;A61K9/1635;;A61K9/282;;A61K9/1652;;A61K31/44;;A61K9/2054;;A61K31/47;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2027;;A61K9/284;;A61K9/0053;;A61K9/28,A61K31/47;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/28;;A61K31/44,,0,0,,,,ACTIVE
26,RS,B1,RS 56894 B1,042-476-064-338-607,2018-04-30,2018,RS P20180161 A,2009-08-13,US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P;;US 2009/0004629 W;;EP 09789125 A,2008-08-13,"PHARMACEUTICAL COMPOSITION OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4- OXOQUINOLINE-3-CARBOXAMIDE AND ADMINISTRATION THEREOF",,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/042-476-064-338-607,Granted Patent,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K47/32;;A61K9/16;;A61K9/20;;A61K9/28;;A61K31/47,,0,0,,,,ACTIVE
27,CN,B,CN 102231990 B,052-378-650-862-683,2013-09-25,2013,CN 200980135449 A,2009-08-13,US 2009/0004629 W;;US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P,2008-08-13,"Pharmaceutical composition of n- [2, 4-bis (1, 1-dimethylethyl)-5- hydroxyphenyl]- 1, 4 -dihydro-4-oxoquinoline-3- carboxamide and administration thereof",,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/052-378-650-862-683,Granted Patent,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K47/32,,0,0,,,,ACTIVE
28,DK,T3,DK 3345625 T3,095-212-596-681-418,2021-02-01,2021,DK 17204189 T,2009-08-13,US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P;;EP 09789125 A,2008-08-13,FARMACEUTISK SAMMENSÆTNING OG INDGIVELSER DERAF,,VERTEX PHARMA,GROOTENHUIS PETER D J;;ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;OVERHOFF KIRK;;BOTFIELD MARTYN;;GROSSI ALFREDO;;VERWIJS MARINUS JACOBUS,,https://lens.org/095-212-596-681-418,Granted Patent,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K9/16;;A61K9/20;;A61K9/28;;A61K31/47,,0,0,,,,ACTIVE
29,EP,A1,EP 3842037 A1,096-132-810-450-781,2021-06-30,2021,EP 20211291 A,2009-08-13,US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P;;EP 17204189 A;;EP 09789125 A;;US 2009/0004629 W,2008-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF,"The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.",VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/096-132-810-450-781,Patent Application,yes,3,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K9/20;;A61K9/16;;A61K9/28;;A61K31/47;;A61P1/10;;A61P1/16;;A61P3/00;;A61P3/06;;A61P3/10;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P11/00;;A61P11/02;;A61P27/02;;A61P35/00;;A61P37/08,,7,7,027-495-322-764-618;;164-990-444-435-834;;062-658-814-888-724;;147-561-926-460-635;;059-603-579-320-605;;139-606-967-003-103;;009-491-011-950-586,1695717;;10.1038/346366a0;;2475911;;10.1126/science.2475911;;10.1016/0092-8674(90)90196-l;;2344617;;2236053;;pmc54973;;10.1073/pnas.87.21.8447;;10.1096/fasebj.4.10.2197151;;2197151;;10.1038/354526a0;;1722027;;7539001;;10.1074/jbc.270.21.12347,"CUTTING, G. R. ET AL., NATURE, vol. 346, 1990, pages 366 - 369;;RIORDAN, J. R. ET AL., SCIENCE, vol. 245, 1989, pages 1073 - 1080;;DEAN, M. ET AL., CELL, vol. 61, 1990, pages 863 - 870;;KEREM, B-S ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 8447 - 8451;;QUINTON, P. M., FASEB J, vol. 4, 1990, pages 2709 - 2727;;DALEMANS ET AL., NATURE LOND, vol. 354, 1991, pages 526 - 528;;PASYKFOSKETT, J. CELL. BIOCHEM., vol. 270, 1995, pages 12347 - 50",PENDING
30,CY,T1,CY 1119945 T1,114-728-265-728-052,2018-12-12,2018,CY 181100229 T,2018-02-26,US 2009/0004629 W;;US 14616309 P;;US 8880108 P;;US 18334509 P;;US 8870408 P;;US 9009608 P;;US 18152709 P,2008-08-13,"ΦΑΡΜΑΚΕΥΤΙΚΗ ΣΥΝΘΕΣΗ Ν-[2,4-ΔΙΣ(1,1-ΔΙΜΕΘΥΛΑΙΘΥΛ)-5-ΥΔΡΟΞΥΦΑΙΝΥΛ]-1,4-ΔΙΥΔΡΟ-4-ΟΞΟΚΙΝΟΛΙΝΟ-3-ΚΑΡΒΟΞΑΜΙΔΙΟΥ ΚΑΙ ΧΟΡΗΓΗΣΗ ΑΥΤΗΣ","Η παρούσα εφεύρεση αφορά σε φαρμακευτικές συνθέσεις που περιλαμβάνουν διασπορά στερεού του Ν-[2,4-Δις(1,1-διμεθυλαιθυλ)-5-υδροξυφαινυλ]-1,4-διυδρο-4-οξοκινολινο-3- καρβοξαμιδίου, μεθόδους βιομηχανικής κατασκευής φαρμακευτικών συνθέσεων της παρούσας εφεύρεσης και μεθόδους χορήγησης φαρμακευτικών συνθέσεων της παρούσας εφεύρεσης.",VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO;;YOUNG CHRISTOPHER,,https://lens.org/114-728-265-728-052,Granted Patent,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K47/32;;A61K9/16;;A61K9/20;;A61K9/28;;A61K31/47,,0,0,,,,ACTIVE
31,US,B2,US 11564916 B2,106-569-906-844-331,2023-01-31,2023,US 202016842480 A,2020-04-07,US 202016842480 A;;US 201615253636 A;;US 201314135323 A;;US 58306609 A;;US 18334509 P;;US 18152709 P;;US 14616309 P;;US 9009608 P;;US 8880108 P;;US 8870408 P,2008-08-13,Pharmaceutical composition and administrations thereof,"The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.",VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,VERTEX PHARMACEUTICALS INCORPORATED (2010-07-28),https://lens.org/106-569-906-844-331,Granted Patent,yes,618,1,33,98,0,A61K9/1635;;A61K9/1652;;A61K9/282;;A61K31/44;;A61K9/2054;;A61K31/47;;A61P11/00;;A61P11/08;;A61P19/00;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/00;;A61P43/00;;A61K31/47;;A61K9/14;;A61K9/1635;;A61K9/282;;A61K9/1652;;A61K31/44;;A61K9/2054;;A61K31/47;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2027;;A61K9/284;;A61K9/0053;;A61K9/28,A61K31/47;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/28;;A61K31/44,,292,0,,,"Pai et al. J. of Cystic Fibrosis, 2006, 5(3), 153-157. (Year: 2006).;;Adde et al. Jornal de Pediatria, 80(6), 2004, 475-782. (Year: 2004).;;Shands https://professionals.ufhealth.org/files/2011/11/1007-drugs-therapy-bulletin.pdf, Drugs &Therapy Bulletin, Nov./Dec. 2007, no pagination. (Year: 2007).;;Birkitt https://www.nps.org.au/australian-prescriber/articles/pharmacokinetics-made-easy-11-designing-dose-regimens, Australian Prescriber, 1996, 19, 76-78. (Year: 1996).;;“Food's Journey through the Digestive System,” Science Learning Hub, Oct. 1, 2019, http://wwwsciencelearn.org.nz/resources/1849-food-s-journey-throuqh-the-digestive-system, published Jul. 1, 2011, 7 pgs.;;“Vertex Pharmaceuticals Initiates Phase 2 Development for CFTR Corrector VX-809 in Patients with Cystic Fibrosis,” Vertex Press Release Mar. 25, 2009, 2 pgs.;;“Vertex Pharmaceuticals Initiates Phase 3 Registration Program for VX-770, an Oral CFTR Potentiator Targeting the Defective Protein Responsible for Cystic Fibrosis,” Vertex Press Release dated May 27, 2009, 3 pgs.;;Agui, Hideo et al., (1971) “Studies on Quinoline Derivatives and Related Compounds, I. A New Synthesis of 1-Alkyl-1, 4-dihydro-4-oxo-3-quinolinecarboxylic Acids,” Journal of Hetercyclic Chemistry, vol. 8, 357-365.;;Aulton, M.E. (Ed.) (2002) Pharmaceutics: The Science of Dosage Design. Ed. Churchill Livingston; pp. 304-305, 1998, 2 pgs.;;European Patent Application No. 06848237.1 (Patent No. 1993360), filed Mar. 31, 2008, by Vertex Pharmaceuticals Inc.: Opposition Submission by Georg Kalhammer and Stephan Teipel, Apr. 12, 2019 (6 pages).;;European Patent Application No. 10708442.8 (Patent No. 2464337), filed Feb. 18, 2010, by Vertex Pharmaceuticals Inc.: Notice of Opposition by Teva Pharmaceutical Industries Ltd., dated Oct. 7, 2019 (20 pages).;;European Patent Application No. 10708442.8 (Patent No. 2464337), Response to Communication pursuant to Rules 70(2) and 70a(2) EPC dated May 12, 2015, 5 pgs.;;Lumacaftor, ChemSpider ID No. 17611836, http://www.chemspider.com/Chemical-Strusture.17611838.hmi, © Royal Society of Chemistry 2019, 4 pgs.;;Rowe et al., “Handbook of Pharmaceutical Excipients,” 6th Edition, 2009, 32 pgs.;;U.S. Appl. No. 16/109,931, filed Aug. 23, 2018, by Keshavarz-Shokri et al.;;U.S. Appl. No. 16/276,887, filed Feb. 15, 2019, by Sara S. Hadida Ruah et al.;;U.S. Appl. No. 16/704,713, filed Decembers, 2019, by Patricia Hurter et al.;;U.S. Appl. No. 16/783,338, filed Feb. 6, 2020, by Ali Keshavarz-Shokri et al.;;U.S. Appl. No. 16/789,945, filed Feb. 13, 2020, by Sara S. Hadida Ruah et al.;;U.S. Appl. No. 16/842,230, filed Apr. 7, 2020, by Sara S. Hadida Ruah et al.;;U.S. Appl. No. 16/842,480, filed Apr. 7, 2020, by William Rowe et al.;;U.S. Appl. No. 61/183,345, filed Jun. 2, 2009, by William Rowe et al.;;Accurso, F. J. et al. (2009) “Final results of a 14- and 28-day study of VX-770 in subjects with CF” J. Cystic Fibrosis, vol. 8, Supplement 2, Abstracts of the 32nd European Cystic Fibrosis Conference, Jun. 10-13, 2009, Abstract 97, p. S25.;;Akama, T. et al. (Jun. 1997) “Design and synthesis of potent antitumor 5,4′-diaminoflavone derivatives based on metabolic considerations” J Med Chem, 40(12):1894-1900.;;Alhalaweh, A. et al. (2015) “Physical stability of drugs after storage above and below the glass transition temperature: Relationship to glass-forming ability” Int J Pharm, 495(1):312-317.;;American College of Chest Physicians (2004) Living Well With COPD: Chronic Bronchitis and Emphysema. Patient Education Guide. Northbrook, IL, USA; Product Code: 5032, 44 pages.;;Archimica (Oct. 2006) Coupling Agen® T3P—The Water Scavenger. High-Performance Amide/Peptide Bond Formations, Dehydrations and Condensations. [online] Retrieved Apr. 11, 2011, from the Internet: http://www.archimica.com/PDF/ARCHIMICA_T3P_Brochure.pdf> (20 pages).;;Ashizawa, K. (2002) Polymorphism and Crystallization of the Pharmaceutical Drugs, pp. 273, 278, 305-317 (Japanese).;;Aulton, M.E. (Ed.) (2002) Pharmaceutics: The Science of Dosage Design. 2nd Ed. Churchill Livingston; pp. 304-321.;;Aulton, M.E. (Ed.) (2002) Pharmaceutics: The Science of Dosage Design. 2nd Ed. Churchill Livingston; p. 116.;;Aulton, M.E. (Ed.) (2007) Pharmaceutics: The Science of Dosage Design. 3rd Ed. Churchill Livingston; p. 340.;;Aungst, B.J. et al. (1987) “Prodrugs for improved oral nalbuphine bioavailability: inter-species differences in the disposition of nalbuphine and its acetylsalicylate and anthranilate esters” Int. J. Pharm., 38:199-209.;;Baghel, S. et al. (2016) “Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs” J Pharm Sci, 105(9): 2527-2544.;;Bauer, K.H. et al. (2007) Lehrbuch der Pharmazeutischen Technologie. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH; pp. 214-217, with English translation.;;Berge, S.M. et al. (1977) “Pharmaceutical Salts” J Pharmac Sci, 66(1):1-19.;;Bernstein, J. et al. (1995) “Patterns in Hydrogen Bonding: Functionality and Graph Set Analysis in Crystals” Angew Chem Int Ed Engl, 34:1555-1573.;;Bombeiri, C. et al. (1998) “Complete mutational screening of the CFTR gene in 120 patients with pulmonary disease” Human Genet, 103:718-722.;;Bombieri et al., “Recommendations for the classification of diseases of CFTR-related disorders,” J. Cyst Fibros 10:2 S86-S102 (2011).;;Brittain, H. (Jul. 2001) “X-ray Diffraction III: Pharmaceutical Applications of X-ray Powder Diffraction” Spectroscopy, 16(7):14-18.;;Brittain, H.G. (Apr. 1997) “Spectral Methods for the Characterization of Polymorphs and Solvates” J Pharm Sci, 86(4):405-412.;;Brown, R.K. et al. (1954) “6-Aminoindole” J Am. Chem Soc, 76(20):5149-5150.;;Brown, R.K. et al. (1955) “Derivatives of Indole, 6-Amino-3-indoleacetic Acid” J Am Chem Soc, 77(14):3839-3842.;;Brown, R.K. et al. (1956) “Some Indole Derivatives Tested for Antitubercular Activity” J Org Chem, 21:261-262.;;Burvall, K.M. et al. (2002) “The tyrosine kinase inhibitor genistein increases basal cAMP and potentiates forskolin-induced cAMP accumulation in A549 human airway epithelial cells” Mol Cell Biol, 240:131-133.;;Byrn, S. et al. (1995) “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations” Pharmaceutical Research, 12(7):945-954.;;Cai, Z-W. et al. (2011) “Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis” Acta Pharmacologica Sinica, 32(6):693-701.;;Caira, M.R. (Jan. 1, 1998) “Crystalline Polymorphism of Organic Compounds” Topics in Chemistry, 198:163-208.;;Carta, A. et al. (2003) “Synthesis and Biological Evaluation of Triazolo[4,5-g]Quinolines, Imidazo[4,5-g]Quinolines and Pyriodo[2,3-g]Quinoxalines. Part II” Heterocycles, 60(4):833-842.;;Chemical Abstracts Service, ‘Registry’ File, RN 174311-74-1. STN Database [online]. Entry Date: Mar. 19, 1996, retrieved on Apr. 25, 2013.;;Chemical Abstracts Service, ‘Registry’ File, RN 325779-54-2. STN Database [online]. Entry Date: Mar. 6, 2001, retrieved on Jan. 28, 2016.;;Chemical Abstracts Service, ‘Registry’ File, RN 329691-97-6. STN Database [online]. Entry Date: Apr. 2, 2001, retrieved on Jan. 28, 2016.;;Chemical Abstracts Service, ‘Registry’ File, RN 329691-99-8. STN Database [online]. Entry Date: Apr. 2, 2001, retrieved on Jan. 28, 2016.;;Chemical Abstracts Service, ‘Registry’ File, RN 329692-01-5. STN Database [online]. Entry Date: Apr. 2, 2001, retrieved on Jan. 28, 2016.;;Chemical Abstracts Service, ‘Registry’ File, RN 329692-03-7. STN Database [online]. Entry Date: Apr. 2, 2001, retrieved on Jan. 28, 2016.;;Chemical Abstracts Service, ‘Registry’ File, RN 329692-05-9. STN Database [online]. Entry Date: Apr. 2, 2001, retrieved on Jan. 28, 2016.;;Chemical Abstracts Service, ‘Registry’ File, RN 329692-14-0. STN Database [online]. Entry Date: Apr. 2, 2001, retrieved on Jan. 28, 2016.;;Chemical Abstracts Service, ‘Registry’ File, RN 625115-91-5. STN Database [online]. Entry Date: Dec. 9, 2003, retrieved on Apr. 25, 2013.;;Chemical Abstracts Service, ‘Registry’ File, RN 629662-49-3. STN Database [online]. Entry Date: Dec. 22, 2003, retrieved on Jul. 24, 2015.;;Chemical Abstracts Service, ‘Registry’ File, RN 849644-14-0; STN Database SciFinder® [online]. Entry Date: Nov. 2, 2004, retrieved on Mar. 25, 2014.;;Cheung, J. et al. (Feb. 2008) “Misfolding of the cystic fibrosis transmembrane conductance regulator and disease” Biochemistry, 47(6):1465-1473.;;Chiou, W.L. et al. (1971) “Pharmaceutical Applications of Solid Dispersion Systems” J Pharm Sci, 60(9):1281-1302.;;Clemence, F. et al. (Jul. 1988) “4-Hydroxy-3-quinolinecarboxamides with antiarthritic and analgesic activities” J Med Chem, 31(7):1453-1462.;;Clunes, M.T. et al. (2008) “Front-runners for pharmacotherapeutic correction of the airway ion transport defect in cystic fibrosis” Current Opinion in Pharmacology, 8(3):292-299.;;Collawn, J.F. et al. (2010) “Targets for cystic fibrosis therapy: proteomic analysis and correction of mutant cystic fibrosis transmembrane conductance regulator” Expert Review of Proteomics, 7(4):495-506.;;Cuthbert, A.W. (2010) “New horizons in the treatment of cystic fibrosis” Br J Pharmacol, 163:173-183.;;Cystic Fibrosis Centre At the Hospital for Sick Children in Toronto, Cystic Fibrosis Mutation Database. [online] Retrieved from: http://www.genet.sickkids.on.ca/cftr/app, on Jul. 20, 2018.;;De Meeus, A. et al. (1998) “Genetic Findings in Congenital Bilateral Aplasia of Vas Deferens Patients and Identification of Six Novel Mutations” Human Mutation, Mutation in Brief, #138 [online], DOI: 10.1002/(SICI)1098-1004(1998)11:6<480::AID-HUMU10>3.0.CO;2-Z, 10 pages. Final publication in vol. 11(6), p. 480.;;Dean, M. et al. (Jun. 1990) “Multiple mutations in highly conserved residues are found in mildly affected cystic fibrosis patients” Cell, 61:863-870.;;Dhar, T.G. M et al. (2003) “3-Cyanoindole-based Inhibitors of Inosine Monophosphate Dehydrogenase: Synthesis and Initial Structure-Activity Relationships” Bioorg. Med. Chem. Lett., 13(20):3557-3560.;;Dif, F. et al. (2004) “Severe osteopenia in CFTR-null mice” Bone, 35:595-603.;;Dohmori, R. et al. (1976) “Synthetic Chemotherapeutic Agents. I. Synthesis of 2-Substituted Thiazolo[5,4-fjquinoline Derivatives” Chem Pharm Bull, 24:130-135.;;Eckford, P.D.W. et al. (2012) “Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Potentiator VX-770 (Ivacaftor) Opens the Defective Channel Gate of Mutant CFTR in a Phosphorylation-dependent but ATP-independent Manner” J Biol Chem, 287(44):36639-36649.;;Erlinger, S. (2011) “Molecular repair of a defective CFTR protein in cystic fibrosis” Clinics and Research in Hepatology and Gastroenterology, 35:254-256.;;European Patent Application No. 06848237.1 (Patent No. 1993360), filed Mar. 31, 2008, by Vertex Pharmaceuticals Inc.: Notice of Opposition by Georg Kalhammer and Stephan Teipel, Nov. 3, 2017 (10 pages).;;Ferec, C. et al. (2012) “Assessing the Disease-Liability of Mutations in CFTR” Cold Spring Harbor Perspect Med, 2:a009480 (13 pages).;;Flume, P. A. et al. (2012) “Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation” Chest, 142:718-724.;;Galietta, L.J.V. et al. (2001) “Novel CFTR Chloride Channel Activators Identified by Screening of Combinatorial Libraries Based on Flavone and Benzoquinolizinium Lead Compounds” J Biol Chem, 276(23):19723-19728.;;Gardner, C.R. et al. (2004) “Drugs as Materials: Valuing Physical Form in Drug Discovery” Nat Rev Drug Discov, 3:926-934.;;Grant, D.J.W. (1999) “Theory and Origin of Polymorphism” in Polymorphism in Pharmaceutical Solids, H.G. Brittain, Ed.; Ch.1, pp. 1-10.;;Grohe, K. et al. (1987) “Synthese von 1-amino-4-chinolon-3-carbonsauren” Liebigs Annalen Der Chemie, 10:871-879.;;Guillory, J.K. (1999) “Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids” in Polymorphism in Pharmaceutical Solids. H.G. Brittain, Ed.; Ch.5, pp. 183-226.;;Guo, J-H. (Jun. 2004) “Lactose in Pharmaceutical Applications” Drug Delivery, vol. 4, No. 5 (7 pages).;;Hama, T. et al. (2003) “Palladium-Catalyzed α-Arylation of Esters and Amides under More Neutral Conditions” J Am Chem Soc, 125(37):11176-11177.;;Hancock, B. and Zografi, G. (1997) “Characteristics and significance of the amorphous state in pharmaceutical systems” J Pharm Sci, 86(1):1-12.;;Hancock, B.C. et al. (2000) “What is the True Solubility Advantage for Amorphous Pharmaceuticals?” Pharmaceutical Research, 17(4):397-404.;;Handbook for Preparing Crystal of Organic Compound—Principle and Know-how, Maruzen Co., Ltd Jul. 25, 2008, pp. 57-84 (Japanese).;;Hansen, K.T. et al. (Aug. 1991) “Carbamate ester prodrugs of dopaminergic compounds: synthesis, stability, and bioconversion” J Pharm Sci, 80(8):793-798.;;Haynes, R.K. et al. (1972) “Amine Oxidation and the Chemistry of Quinone Imines. Part I. 3-Methoxy-4-t-butylaniline” J Chem Soc, Perkins Trans, 1:396-408.;;Hegde, S. et al. (2006) “To Market, To Market—2005” Annu Rep Med Chem, 41 :439-477.;;Heilbron, I.M. et al. (1928) “The Intermolecular Condensation of Acetylmethylanthranilic Acid by Means of Phosphorus Pentachloride and the Formation of a Complex isoCyanine Dye” J Chem Soc, pp. 934-941.;;Hennequin, L.F. et al. (1999) “Design and Structure-Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors” J Med Chem, 42(26):5369-5389.;;Hester, J.B. et al. (1964) “Enzyme Inhibitory Activity of 3-(2-Aminobutyl)indole Derivatives” J Med Chem, 7(3):274-279.;;Hoffman, H.E. et al. (2005) “Allele-Specific Inhibitors of Protein Tyrosine Phosphatases” J Am Chem Soc, 127(9):2824-2825.;;Huang, Y. and Dai, W. G. (2014) “Fundamental aspects of solid dispersion technology for poorly soluble drugs” Acta Pharm Sin B, 4(1):18-25.;;Imanishi, T. et al. (1996) “Evidence that a Hybrid Molecule of Norfloxacin and Biphenylacetic Acid is a Potent Antagonist at the GABAA Receptor” Neuropharmacology, 35(9/10):1271-1277.;;International Patent Application No. PCT/US2006/048810, filed Dec. 21, 2006, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Jul. 26, 2007.;;International Patent Application No. PCT/US2006/048900, filed Dec. 21, 2006, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated May 25, 2007.;;International Patent Application No. PCT/US2006/049421, filed Dec. 28, 2006, by Vertex Pharmaceuticals, Inc.: International Search Report and Written Opinion, dated Sep. 25, 2007.;;International Patent Application No. PCT/US2007/068857, filed May 14, 2007, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Sep. 9, 2008.;;International Patent Application No. PCT/US2008/010728, filed Sep. 15, 2008, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Jul. 14, 2010.;;International Patent Application No. PCT/US2009/004629, filed Aug. 13, 2009, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Mar. 24, 2011.;;International Patent Application No. PCT/US2010/024609, filed Feb. 18, 2010, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Jun. 1, 2010.;;International Patent Application No. PCT/US2010/028062, filed Mar. 19, 2010, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated May 27, 2010.;;International Patent Application No. PCT/US2010/028069, filed Mar. 19, 2010, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Aug. 25, 2010.;;International Patent Application No. PCT/US2010/059920, filed Dec. 10, 2010, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Feb. 3, 2011.;;International Patent Application No. PCT/US2011/029276, filed Mar. 21, 2011, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated May 11, 2011.;;International Patent Application No. PCT/US2011/033687, filed Apr. 22, 2011, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Aug. 30, 2011.;;International Patent Application No. PCT/US2011/033689, filed Apr. 22, 2011, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Aug. 30, 2011.;;International Patent Application No. PCT/US2011/033693, filed Apr. 22, 2011, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Aug. 30, 2011.;;International Patent Application No. PCT/US2011/037457, filed May 20, 2011, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Jul. 13, 2011.;;International Patent Application No. PCT/US2011/049467, filed Aug. 26, 2011, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Apr. 2, 2012.;;International Patent Application No. PCT/US2012/034578, filed Apr. 20, 2012, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Mar. 21, 2013.;;International Patent Application No. PCT/US2012/063398, filed Nov. 2, 2012, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Jan. 23, 2013.;;International Patent Application No. PCT/US2013/028097, filed Feb. 27, 2013, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated May 10, 2013.;;International Patent Application No. PCT/US2013/044838, filed Jun. 7, 2013, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Aug. 5, 2013.;;International Patent Application No. PCT/US2015/054565, filed Oct. 7, 2015, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Jan. 11, 2016.;;International Patent Application No. PCTUS2005/022768, filed Jun. 24, 2005, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Jul. 25, 2006.;;International Search Report and Written Opinion dated Jan. 11, 2016, in International Patent Application No. PCT/US2015/054577.;;Irie, K. et al. (1995) “Synthesis of 6-Substituted Indolactams by Microbial Conversion” Tetrahedron, 51(22):6255-6266.;;Iskandarani, B. et al. (1993) “Simultaneous Optimization of Capsule and Tablet Formulation Using Response Surface Methodology” Drug Dev Industrial Pharmacy, 19(16):2089-2101.;;Ito, Y. et al. (1996) “Inhibition of GABAA Receptor Chloride Channel by Quinolones and Norfloxacin-Biphenylacetic Acid Hybrid Compounds” Neuropharmacology, 35(9/10):1263-1269.;;Jermain, S. V. et al. (2018) “Amorphous solid dispersions and nanocrystal technologies for poorly water-soluble drug delivery—An update” Int J Pharm, 535(1-2):379-392.;;Jivraj, M. et al. (Feb. 2000) “An overview of the different excipients useful for the direct compression of tablets” PSTT, 3(2):58-63.;;Johannesson, J. et al. (Aug. 2012) “CFTR Regulates Early Pathogenesis of Chronic Obstructive Lung Disease in ßENaC-Overexpressing Mice” PLoS ONE, 7(8):e44059 (11 pages).;;Johnson, H.E. et al. (1963) “Reactions of Indole. IV. The Synthesis of Some Aminoindoles” J Org Chem, 28(10):2794-2797.;;Jones, A.M. and J.M. Helm (2009) “Emerging Treatments in Cystic Fibrosis” Drugs, 69(14):1903-1910.;;Kaminsky, D. et al. (1968) “Quinolone Antibacterial Agents. OxolinicAcid and Related Compounds” J Med Chem, 11(1):160-163.;;Kapranov, N.I. et al. (2004) “Cystic fibrosis: Recent Progress and Problems” Medical Genetics, 3(9):398-412, with English translation.;;Kurata, H. et al. (2004) “A novel class of apical sodium-dependent bile acid transporter inhibitors: the amphiphilic4-oxo-1-phenyl-1,4-dihydroquinoline derivatives” Bioorg. Med. Chem. Lett., 14:1183-1186.;;Leusen, F.J.J. (1996) “Ab initio prediction of polymorphs” J Crystal Growth, 166:900-903.;;Levine, M.H. et al. (2005) “CFTR-Regulated Chloride Transport at the Ocular Surface in Living Mice Measured by Potential Differences” Invest Ophthal Vis Sci, 46(4):1428-1434.;;Loo, T.W. et al. (2011) “Corrector-mediated rescue of misprocessed CFTR mutants can be reduced by the P-glycoprotein drug pump” Biochem Pharmacol, 83(3):345-354.;;Ma, T. et al. (2002) “High-affinity Activators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Conductance Identified by High-Throughput Screening” J. Biol. Chem., 277(40):37235-37241.;;Mall, M. et al. (2000) “Effect of genistein on native epithelial tissue from normal individuals and CF patients and on ion channels expressed in Xenopus oocytes” Br J Pharmacol, 130:1884-1892.;;Mandour, A.H. et al. (1999) “Aminolysis and Hydrolysis of Indolyl Oxazolones” Egyptian J Chem, 42(3):251-266.;;Marivingt-Mounir, C. et al. (Feb. 2004) “Synthesis, SAR, crystal structure, and biological evaluation of benzoquinoliziniums as activators of wild-type and mutant cystic fibrosis transmembrane conductance regulator channels” J Med Chem, 47(4):962-972.;;Martínez-Ohárriz, M.C. (1994) “Polymorphism of diflunisal: Isolation and solid-state characteristics of a new crystal form” J Pharm Sci, 83:174-177.;;Mashkovskiy, M.D., Medicaments. Manual for Doctors. vol. 1, 14th Edition. Moscow: LLC “Novaya Volna”, 2001; p. 11.;;Miles, E.W. and R.S. Phillips (1985) “Photoinactivation and photoaffinity labeling of tryptophan synthase α2β2 complex by the product analogue 6-azido-L-tryptophan”Biochem, 24(17):4694-4703.;;Motherwell, W.D.S. et al. (2000) “Automated assignment of graph-set descriptors for crystallographically symmetric molecules” Acta Cryst, B56:466-473.;;Mullins, J.D. et al. (1960) “Some Pharmaceutical Properties of Novobiocin” J. Am. Pharm. Assoc. 49(4):245-248.;;Newman, A. et al. (2012) “Assessing the performance of amorphous solid dispersions” J Pharm Sci, 101(4):1355-1377.;;Nishikawa, Y. et al. (1989) “Synthesis and Antiallergic Activity of N-[4-(4-Diphenylmethyl-1-piperazinyl)butyl]-1,4-dihydro-4-oxopyridine-3-carboxamides” Chem Pharm Bull, 37(5):1256-1259.;;Noone, P.G. et al. (2001) “‘CFTR-opathies’: disease phenotypes associated with cystic fibrosis transmembrane regulator gene mutations” Respiratory Research, 2(6):1-5.;;Nosova, E.V., et al. (2002) “Synthesis of new fluorinated derivatives of Quinolinecarboxylic acids” Chem. of Heter. Compounds, 38(8):922-928. Translated from: Khimiya Geterotsiklicheskikh Soedinenii, No. 8, pp. 1060-1066.;;Notice of Allowability for U.S. Appl. No. 14/579,098, dated Apr. 18, 2016.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 13/290,491, dated Oct. 25, 2012.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 13/871,349, dated Apr. 17, 2015.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 13/871,349, dated Aug. 12, 2014.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 13/871,349, dated Oct. 13, 2015.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 13/887,839, dated Feb. 2, 2015.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 13/887,839, dated Jul. 7, 2014.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 13/887,839, dated Oct. 16, 2014.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 13/887,839, dated Sep. 30, 2015.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/031,360, dated Aug. 14, 2014.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/298,245, dated Jul. 21, 2015.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/298,245, dated Nov. 12, 2015.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/326,930, dated Aug. 14, 2015.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/326,930, dated Dec. 8, 2015.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/334,902, dated Feb. 18, 2016.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/334,902, dated Oct. 19, 2015.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/532,791, dated Jul. 24, 2015.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/532,791, dated Mar. 1, 2016.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/532,791, dated Nov. 6, 2015.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/567,475, dated Jan. 5, 2016.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/567,475, dated Sep. 21, 2015.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/579,098, dated Feb. 1, 2016.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/579,098, dated May 12, 2016.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/656,043, dated Aug. 4, 2016.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/687,286, dated Feb. 10, 2016.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/687,286, dated May 19, 2016.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/687,286, dated Sep. 28, 2016.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/877,914, dated Jul. 27, 2016.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/877,914, dated Nov. 14, 2016.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/925,804, dated May 17, 2016, Celia C. Chang.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 15/001,036, dated Feb. 10, 2017.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 15/073,591, dated Sep. 28, 2016, Celia C. Chang.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/027,791, dated Jul. 31, 2015.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/687,286, dated Dec. 1, 2017.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/687,286, dated May 9, 2018.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 15/001,036, dated May 1, 2018.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 15/152,092, dated May 17, 2018.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 15/342,999, dated Apr. 17, 2018.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/676,205, dated May 24, 2018.;;Notice of Opposition for EP Patent Application No. 06848237.1, dated Nov. 11, 2017.;;Paranjape, S.M. et al. (2008) “Atypical Cystic fibrosis and CFTR-Related Diseases” Clinic Rev Allerg Immunol, 35(3):116-123.;;Paritala, H. et al. (2009) “Benzo(h)quinoline derivatives as G-quadruplex binding agents” Bioorg Med Chem Lett, 19(8):1584-1587.;;Patel, H. et al. (Aug. 2011) “New pharmaceutical excipients in solid dosage forms—A review” Intl J Pharm & Life Sci, 2(8):1006-1019.;;Pedemonte, N. et al. (2005) “Phenylglycine and sulfonamide correctors of defective AF508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating” Molecular Pharmacology, 67(5):1797-1807.;;Pedemonte, N. et al. (2005) “Small-molecule correctors of defective AF508-CFTR cellular processing identified by high-throughput screening” J Clin Invest, 115(9):2564-2571.;;Pencharz, P.D. and P.R. Durie (2000) “Pathogenesis of malnutrition in cystic fibrosis, and its treatment” Clin Nutr, 19(6):387-394.;;Pérez-Guille, B. et al. (2004) “Pharmacokinetics of a cephalone (CQ-M-EPCA) in rats after oral, intraduodenal and intravenous administration” Intl J Pharm, 282(1-2):87-94.;;Porst, H. and L. Kny (1985) “Zur StrukturderAbbauprodukte von Neostigminbromid (On the Structure of Degradation Products of Neostigmine bromide” Pharmazie, 40(5):325-328. German with English translation.;;Pubchem Compound No. CID 29877; Database Record No. 19962-04-0; Create Date Jul. 19, 2005 [online], Retrieved from: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=29877; on Jan. 16, 2014 (4 pages).;;Rahman, Z. et al. (2013) “Tacrolimus Properties and Formulations: Potential Impact of Product Quality on Safety and Efficacy” 1-39.;;Roberts, R.M. (1949) “The reaction of diarylformamidines with ethyl malonate” J Org Chem, 14(2):277-284.;;Sashida, H. et al. (1990) “Studies of Seven Membered Heterocycles. XXXII. Synthesis of N-Unsubstituted 1H-1, 4-Benzodiazepines Stabilized by Intramolecular Hydrogen Bonding” Chem Pharm Bull, 38(11):2919-2925.;;Sekiguchi, K. et al. (1961) “Studies on Absorption of Eutectic Mixture. I. A Comparison of the Behavior of Eutectic Mixture of Sulfathazole and that of Ordinary Sulfathiazole in Man” Chem. Pharm. Bull. 9:866-872.;;Sen, A.B. et al. (1947) “Synthesis of Substituted Dinitrophenyl Ketones, and Phenylacetic Acids. Part I.” J. Indian Chem. Soc., 24:268-270.;;Sen, A.B., et al. (1948) “Synthesis of Substituted Dinitro Phenylketones and Phenylacetic Acids. Part III.” J Indian Chem Soc, 25:282-284.;;Sen, A.B., et al. (1948) “Synthesis of Substituted Dinitrophenyl Ketones and Phenylacetic Acids. Part IV.” J Indian Chem Soc, 25(8):403-404.;;Settimj, G. et al. (1988) “β-Carbolines as agonistic or antagonistic benzodiazepine receptor ligands. 1. Synthesis of some 5-, 6- and 7-amino derivatives of 3-methoxycarbonyl-β-carboline (β-CCM) and of 3-ethoxycarbonyl-β-carboline (β-CCE)” J Heterocyclic Chem, 25(5):1391-1397.;;Shead et al. (2007) “Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone” Thorax, 62:650-651.;;Shioji, Y. (Jan. 2, 20037) Manufacture Technology of Solid Preparation. CMC Publishing Co., Ltd.; pp. 9, 12, and 13 (Japanese).;;Showalter, H.D.H. et al. (1996) “Concise Syntheses of the Novel 1H-Pyrrolo[3,2-g]quinazoline Ring System and its [2,3-f] Angular Isomer” J Org Chem, 61 (3):1155-1158.;;Silverman, R.B. (1992) The Organic Chemistry of Drug Design and Drug Action. San Diego, CA: Academic Press; pp. 5-51.;;Sloane, P.A. et al. (2010) “Translational readthrough of premature stop codons combined with CFTR potentiation: potential for combination CFTR therapy” Pediatric Pulmonology, 45(33):313, Abstract 264.;;Sloane, P.A. et al. (2012) “A Pharmacologic Approach to Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Smoking Related Lung Disease” PLoS ONE, 7(6):e39809 (13 pages).;;Srivastava, S.K. et al. (2000) “Quinolones: Novel Probes in Antifilarial Chemotheraphy” J Med Chem, 43(11):2275-2279.;;Stella, V.J. et al. (1999) “Aqueous Solubility and Dissolution Rate Does Not Adequately Predict in vivo Performance: A probe Utilizing Some N-Acyloxymethyl Phenytoin Prodrugs” J Pharm Sci, 88(8):775-779.;;Summary of Product Characteristics for Telxir® and Agenerase®.;;Swanepoel, E. et al. (2003) “Quality evaluation of generic drugs by dissolution test: changing the USP dissolution medium to distinguish between active and non-active mebendazole polymorphs” Eur J Pharma Biopharma, 55:345-349.;;Tanno, F et al. (2004) “Evaluation of Hypromellose Acetate Succinate (HPMCAS) as a Carrier in Solid Dispersions” Drug Dev Ind Pharm, 30(1):9-17.;;Tao, T. (Dec. 31, 2011) “The progress and applications of flavoring and taste-masking technologies in new oral dosage forms” Shanghai Medical & Pharmaceutical Journal, 32(5):252-255 (Chinese; English Abstract on p. 252).;;Thomas, V.H. et al. (2006) “The road map to oral bioavailability: an industrial perspective” Expert Opin Drug Metabol Toxicol, 2(4):591-608.;;Thomson Scientific, Database WPI, Accession No. 2001-425173; Week 200145.;;Thomson, S.A. et al. (2009) “Minitablets: New Modality to Deliver Medicines to Preschool-Aged Children” Pediatrics, 123:e235 (6 pages).;;Tissen, C. et al. (2011) “Development of mini-tablets with 1 mm and 2 mm diameter” Int J Pharmaceutics, 416:164-170.;;Tonghui, M.A. et al. (2002) “High-affinity Activators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Conductance Identified by High-throughput Screening” J Biol Chem, 277(40):37235-37241.;;Tsui, L-C. (1992) “Mutations and Sequence Variations Detected in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene: A Report From the Cystic Fibrosis Genetic Analysis Consortium” Human Mutation, 1:197-203.;;Tzetis, M. et al. (2001) “CFTR gene mutations-including three novel nucleotide substitutions-and haplotype background in patients with asthma, disseminated bronchiectasis and chronic obstructive pulmonary disease” Hum Genet, 108:216-221.;;U.S. Department of Health and Human Services, Food and Drug Administration (Dec. 2002) Guidance for Industry. Food-Effect Bioavailability and Fed Bioequivalence Studies. (9 pages).;;U.S. Appl. No. 60/754,381, filed Dec. 28, 2005, by Patricia Hurter. et al.",ACTIVE
32,HU,T2,HU E053357 T2,191-986-738-225-645,2021-06-28,2021,HU E17204189 A,2009-08-13,US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P,2008-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF,,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/191-986-738-225-645,Amended Patent,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K9/16;;A61K9/20;;A61K9/28;;A61K31/47,,0,0,,,,PENDING
33,AU,B2,AU 2009/282419 B2,046-546-505-522-642,2016-05-19,2016,AU 2009/282419 A,2009-08-13,US 18334509 P;;US 8870408 P;;US 9009608 P;;US 18152709 P;;US 14616309 P;;US 8880108 P;;US 2009/0004629 W,2008-08-13,Pharmaceutical composition and administrations thereof,"The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline- 3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.",VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/046-546-505-522-642,Granted Patent,no,1,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K47/32,,0,0,,,,ACTIVE
34,KR,A,KR 20170072950 A,106-993-982-332-357,2017-06-27,2017,KR 20177016117 A,2009-08-13,US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P;;US 2009/0004629 W,2008-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF,"본 발명은 N-[2,4-비스(1,1-디메틸에틸)-5-히드록시페닐]-1,4-디히드로-4-옥소퀴놀린-3-카르복스아미드의 고체 분산물을 포함하는 제약 조성물, 본 발명의 제약 조성물의 제조 방법 및 본 발명의 제약 조성물의 투여 방법에 관한 것이다.",VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/106-993-982-332-357,Patent Application,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K9/28;;A61K9/20;;A61K31/47;;A61K47/32;;A61K47/38,,0,0,,,,DISCONTINUED
35,SI,T1,SI 2328618 T1,167-344-007-743-807,2018-04-30,2018,SI 200931803 T,2009-08-13,US 14616309 P;;US 8880108 P;;US 18334509 P;;US 8870408 P;;US 9009608 P;;US 18152709 P;;US 2009/0004629 W;;EP 09789125 A,2008-08-13,"PHARMACEUTICAL COMPOSITION OF N-(2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL)-1,4-DIHYDRO-4- OXOQUINOLINE-3-CARBOXAMIDE AND ADMINISTRATION THEREOF",,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/167-344-007-743-807,Granted Patent,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K47/00;;A61K9/00;;A61K31/00,,0,0,,,,ACTIVE
36,KR,A,KR 20190143497 A,019-647-850-848-049,2019-12-30,2019,KR 20197037948 A,2009-08-13,US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P;;US 2009/0004629 W,2008-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF,"본 발명은 N-[2,4-비스(1,1-디메틸에틸)-5-히드록시페닐]-1,4-디히드로-4-옥소퀴놀린-3-카르복스아미드의 고체 분산물을 포함하는 제약 조성물, 본 발명의 제약 조성물의 제조 방법 및 본 발명의 제약 조성물의 투여 방법에 관한 것이다.",VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/019-647-850-848-049,Patent Application,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K9/28;;A61K9/20;;A61K31/47;;A61K47/32;;A61K47/38,,0,0,,,,DISCONTINUED
37,UA,C2,UA 102261 C2,117-163-940-797-726,2013-06-25,2013,UA A201102840 A,2009-08-13,US 8870408 P;;US 2009/0004629 W,2008-08-13,"PHARMACEUTICAL COMPOSITIONS COMPRISING A SOLID DISPERSION OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXAMIDE","The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.",VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/117-163-940-797-726,Limited Patent,no,0,0,1,98,0,,A61K31/47;;A61K9/20;;A61P19/04,,0,0,,,,EXPIRED
38,US,A1,US 2010/0074949 A1,078-840-528-017-081,2010-03-25,2010,US 58306609 A,2009-08-13,US 58306609 A;;US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P,2008-08-13,Pharmaceutical composition and administration thereof,"The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.",ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,VERTEX PHARMACEUTICALS INCORPORATED (2010-07-28),https://lens.org/078-840-528-017-081,Patent Application,yes,2,125,33,98,0,A61K9/1635;;A61K9/1652;;A61K9/282;;A61K31/44;;A61K9/2054;;A61K31/47;;A61P11/00;;A61P11/08;;A61P19/00;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/00;;A61P43/00;;A61K31/47;;A61K9/14;;A61K9/1635;;A61K9/282;;A61K9/1652;;A61K31/44;;A61K9/2054;;A61K31/47;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2027;;A61K9/284;;A61K9/0053;;A61K9/28,A61K9/28;;A61K9/42;;A61K9/44;;A61K31/47;;A61P3/00;;A61P19/10,424/467;;514/312;;424/474;;424/476,1,0,,,"Aulton, Pharmaceutics: The science of dosage design, 1988, Churchill Livingston, second edition, pages 304-321",DISCONTINUED
39,CY,T1,CY 1123901 T1,136-669-387-588-466,2022-05-27,2022,CY 211100146 T,2021-02-22,US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P;;EP 09789125 A;;US 2009/0004629 W,2008-08-13,ΦΑΡΜΑΚΕΥΤΙΚΗ ΣΥΝΘΕΣΗ ΚΑΙ ΧΟΡΗΓΗΣΕΙΣ ΑΥΤΗΣ,"Η παρούσα εφεύρεση αφορά σε φαρμακευτικές συνθέσεις που περιλαμβάνουν στερεά διασπορά Ν-[2,4-δις(1,1-διμεθυλαιθυλ)-5-υδροξυφαινυλ]-1,4-διυδρο-4- οξοκινολίνο-3-καρβοξαμιδίου, μεθόδους παραγωγής φαρμακευτικών συνθέσεων της παρούσας εφεύρεσης και μεθόδους χορήγησης φαρμακευτικών συνθέσεων της παρούσας εφεύρεσης.",VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/136-669-387-588-466,Granted Patent,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K9/16;;A61K9/20;;A61K9/28;;A61K31/47,,0,0,,,,ACTIVE
40,MX,B,MX 366161 B,139-732-312-104-955,2019-07-01,2019,MX 2014008855 A,2009-08-13,US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P;;US 2009/0004629 W,2008-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF.,"The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-ox oquinoline- 3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.",VERTEX PHARMACEUTICAL INCORPORATED,PETER D J GROOTENHUIS;;WILLIAM ROWE;;PATRICIA HURTER;;CHRISTOPHER YOUNG;;KIRK DINEHART;;MARINUS JACOBUS VERWIJS;;KIRK OVERHOFF;;MARTYN BOTFIELD;;ALFREDO GROSSI,,https://lens.org/139-732-312-104-955,Granted Patent,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K31/47;;A61K47/32,,0,0,,,,ACTIVE
41,PL,T3,PL 3345625 T3,011-468-084-113-179,2021-06-14,2021,PL 17204189 T,2009-08-13,US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P;;EP 17204189 A;;EP 09789125 A;;US 2009/0004629 W,2008-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF,,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/011-468-084-113-179,Patent Application,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K9/16;;A61K9/20;;A61K9/28;;A61K31/47,,0,0,,,,PENDING
42,EP,A1,EP 3345625 A1,174-038-337-283-581,2018-07-11,2018,EP 17204189 A,2009-08-13,US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P;;EP 09789125 A;;US 2009/0004629 W,2008-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF,"The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.",VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/174-038-337-283-581,Patent Application,yes,3,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K47/32,,10,9,011-275-553-053-877;;164-990-444-435-834;;027-495-322-764-618;;062-658-814-888-724;;115-252-470-991-090;;147-561-926-460-635;;059-603-579-320-605;;139-606-967-003-103;;009-491-011-950-586,1699127;;10.1038/347382a0;;2475911;;10.1126/science.2475911;;1695717;;10.1038/346366a0;;10.1016/0092-8674(90)90196-l;;2344617;;10.1126/science.2570460;;2570460;;2236053;;pmc54973;;10.1073/pnas.87.21.8447;;10.1096/fasebj.4.10.2197151;;2197151;;10.1038/354526a0;;1722027;;7539001;;10.1074/jbc.270.21.12347,"GREGORY, R. J. ET AL., NATURE, vol. 347, 1990, pages 382 - 386;;RICH, D. P. ET AL., NATURE, vol. 347, 1990, pages 358 - 362;;RIORDAN, J. R. ET AL., SCIENCE, vol. 245, 1989, pages 1066 - 1073;;CUTTING, G. R. ET AL., NATURE, vol. 346, 1990, pages 366 - 369;;DEAN, M. ET AL., CELL, vol. 61, 1990, pages 863 - 870;;KEREM, B-S. ET AL., SCIENCE, vol. 245, 1989, pages 1073 - 1080;;KEREM, B-S ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 8447 - 8451;;QUINTON, P. M., FASEB J., vol. 4, 1990, pages 2709 - 2727;;DALEMANS ET AL., NATURE LOND., vol. 354, 1991, pages 526 - 528;;PASYK; FOSKETT, J. CELL. BIOCHEM., vol. 270, 1995, pages 12347 - 50",INACTIVE
43,ME,B,ME 03019 B,022-265-075-128-802,2018-10-20,2018,ME P5418 A,2009-08-13,US 14616309 P;;US 8880108 P;;US 18334509 P;;US 8870408 P;;US 9009608 P;;US 18152709 P;;EP 09789125 A;;US 2009/0004629 W,2008-08-13,"PHARMACEUTICAL COMPOSITION OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4- OXOQUINOLINE-3-CARBOXAMIDE AND ADMINISTRATION THEREOF",,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/022-265-075-128-802,Granted Patent,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K31/47;;A61K9/16;;A61K9/20;;A61K9/28;;A61K47/32,,0,0,,,,ACTIVE
44,BR,A2,BR PI0916877 A2,036-594-009-051-398,2016-02-10,2016,BR PI0916877 A,2009-08-13,US 2009/0004629 W;;US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P,2008-08-13,composição farmacêutica e administração da mesma,,VERTEX PHARMA,GROSSI ALFREDO;;YOUNG CHRISTOPHER;;OVERHOFF KIRK;;DINEHART KRIK;;VERWIJS MARINUS JACOBUS;;BOTFIELD MARTYN;;HURTER PATRICIA;;GROOTENHUIS PETER D J;;ROWE WILLIAM,,https://lens.org/036-594-009-051-398,Patent Application,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K47/32,,0,0,,,,DISCONTINUED
45,CA,C,CA 2733908 C,101-048-534-605-755,2017-05-30,2017,CA 2733908 A,2009-08-13,US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P;;US 2009/0004629 W,2008-08-13,"PHARMACEUTICAL COMPOSITION COMPRISING A SOLID DISPERSION OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXAMIDE","The present invention relates to pharmaceutical compositions comprising a solid dispersion of N- [2,4-Bis( 1, 1-dimethylethyl)-5 -hydroxyphenyl]- 1,4-dihydro-4-oxoquinoline-3-carboxamide, and a polymer, wherein Compound 1 is present in an amount of about 80% by weight of the solid dispersion.",VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/101-048-534-605-755,Granted Patent,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K47/32,,0,0,,,,ACTIVE
46,US,A1,US 2017/0087144 A1,128-878-100-794-272,2017-03-30,2017,US 201615253636 A,2016-08-31,US 201615253636 A;;US 201314135323 A;;US 58306609 A;;US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P,2008-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF,"The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.",VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,VERTEX PHARMACEUTICALS INCORPORATED (2010-07-28),https://lens.org/128-878-100-794-272,Patent Application,yes,0,43,33,98,0,A61K9/1635;;A61K9/1652;;A61K9/282;;A61K31/44;;A61K9/2054;;A61K31/47;;A61P11/00;;A61P11/08;;A61P19/00;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/00;;A61P43/00;;A61K31/47;;A61K9/14;;A61K9/1635;;A61K9/282;;A61K9/1652;;A61K31/44;;A61K9/2054;;A61K31/47;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2027;;A61K9/284;;A61K9/0053;;A61K9/28,A61K31/47;;A61K9/00;;A61K9/20;;A61K9/28,,0,0,,,,ACTIVE
47,HK,A1,HK 1256805 A1,199-548-963-545-670,2019-10-04,2019,HK 18115889 A,2018-12-11,US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P,2008-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF,,VERTEX PHARMA,WILLIAM ROWE;;PATRICIA HURTER;;CHRISTOPHER YOUNG;;KIRK DINEHART;;MARINUS JACOBUS VERWIJS;;KIRK OVERHOFF;;PETER D J GROOTENHUIS;;MARTYN BOTFIELD;;ALFREDO GROSSI,,https://lens.org/199-548-963-545-670,Patent Application,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K/,,0,0,,,,PENDING
48,US,B2,US 10646481 B2,028-511-508-305-755,2020-05-12,2020,US 201615253636 A,2016-08-31,US 201615253636 A;;US 201314135323 A;;US 58306609 A;;US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P,2008-08-13,Pharmaceutical composition and administrations thereof,"The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.",VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,VERTEX PHARMACEUTICALS INCORPORATED (2010-07-28),https://lens.org/028-511-508-305-755,Granted Patent,yes,586,10,33,98,0,A61K9/1635;;A61K9/1652;;A61K9/282;;A61K31/44;;A61K9/2054;;A61K31/47;;A61P11/00;;A61P11/08;;A61P19/00;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/00;;A61P43/00;;A61K31/47;;A61K9/14;;A61K9/1635;;A61K9/282;;A61K9/1652;;A61K31/44;;A61K9/2054;;A61K31/47;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2027;;A61K9/284;;A61K9/0053;;A61K9/28,A61K31/47;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/28;;A61K31/44,,228,95,035-502-640-621-586;;007-364-858-655-289;;032-787-417-624-429;;053-146-386-146-971;;036-615-334-899-923;;008-626-891-695-69X;;068-964-684-276-722;;001-515-230-354-103;;071-229-769-364-518;;009-214-187-079-899;;022-856-724-325-967;;104-949-654-022-72X;;066-363-363-768-682;;057-817-191-735-303;;029-333-527-027-348;;054-244-985-977-967;;001-428-648-997-776;;056-638-311-293-15X;;076-110-890-744-671;;145-186-078-287-715;;027-221-502-208-338;;098-736-003-900-491;;013-424-688-679-155;;009-649-732-042-999;;085-916-809-833-140;;112-695-576-345-242;;046-571-157-785-490;;053-100-120-065-353;;033-320-756-429-035;;017-546-773-754-026;;063-071-876-629-174;;100-065-282-911-868;;038-314-785-473-941;;077-598-286-712-276;;132-427-840-109-877;;039-754-651-973-866;;032-505-434-864-493;;026-840-498-321-579;;062-689-498-926-62X;;030-805-358-020-521;;025-757-826-261-429;;033-678-032-429-167;;152-258-369-458-434;;023-896-000-848-570;;086-360-270-880-378;;030-260-572-406-495;;098-080-328-349-838;;045-119-461-485-524;;020-794-364-767-791;;027-331-697-961-617;;033-336-884-979-126;;126-602-907-030-126;;081-496-534-881-771;;069-032-627-438-103;;071-304-321-401-613;;074-925-352-415-074;;017-658-658-408-271;;093-955-103-615-442;;051-124-133-953-53X;;090-073-967-022-843;;055-354-396-824-448;;152-258-369-458-434;;004-690-579-902-587;;108-235-177-512-304;;106-691-342-610-490;;106-691-342-610-490;;020-889-257-201-858;;059-009-904-687-901;;055-770-611-246-680;;116-767-982-370-369;;039-491-002-797-40X;;045-658-663-935-397;;011-652-300-334-604;;010-920-169-174-749;;062-723-654-165-356;;062-658-814-888-724;;024-966-947-509-122;;022-668-140-507-507;;024-868-418-933-308;;028-220-491-793-982;;032-755-979-900-628;;072-195-862-531-871;;043-258-304-299-127;;075-776-764-795-181;;002-768-392-943-383;;015-714-720-040-924;;050-596-953-379-616;;000-639-832-364-075;;016-577-724-681-620;;113-471-298-037-71X;;126-627-081-808-35X;;023-738-145-985-433;;001-603-403-816-864;;059-034-133-564-253;;133-624-477-716-080,10.1016/s1569-1993(09)60101-6;;10.1002/jps.2600660104;;833720;;10.1002/anie.199515551;;9921909;;10.1007/s004390050897;;10.1021/js960238e;;9109040;;10.1021/ja01649a045;;10.1021/ja01619a047;;10.1021/jo01108a619;;10.1023/a:1020655724911;;12487380;;10.1023/a:1016241927429;;7494814;;pmc4009972;;21642944;;10.1038/aps.2011.71;;10.1007/3-540-69178-2_5;;10.3987/com-02-9687;;10.1016/j.coph.2008.04.006;;pmc2517236;;18468487;;pmc2927865;;20653506;;10.1586/epr.10.45;;10.1111/j.1476-5381.2010.01137.x;;pmc3085876;;21108631;;10.1002/(sici)1098-1004(1998)11:6<480::aid-humu9>3.0.co;2-4;;10200050;;10200051;;10.1002/(sici)1098-1004(1998)11:6<480::aid-humu10>3.3.co;2-q;;10.1002/(sici)1098-1004(1998)11:6<480::aid-humu10>3.0.co;2-z;;10.1002/(sici)1098-1004(1998)11:6<480::aid-humu9>3.3.co;2-w;;14505670;;10.1016/s0960-894x(03)00757-1;;15336594;;10.1016/j.bone.2004.05.021;;1269056;;10.1248/cpb.24.130;;pmc3481266;;10.1074/jbc.m112.393637;;22942289;;10.1016/j.clinre.2011.01.003;;21349786;;22383668;;pmc3435140;;10.1378/chest.11-2672;;10.1074/jbc.m101892200;;11262417;;10.1002/jlac.198719870842;;10870982;;10.1023/a:1007516718048;;1686464;;10.1002/jps.2600800819;;10.1039/jr9280000934;;10.1021/jm990345w;;10639280;;14204959;;10.1021/jm00333a006;;15740097;;10.1021/ja043378w;;10.1016/s0028-3908(96)00058-5;;9014142;;10.1016/0040-4020(95)00298-m;;10.3109/03639049309069343;;10.1016/s0028-3908(96)00057-3;;9014141;;10664574;;10.1016/s1461-5347(99)00237-0;;10.1021/jo01045a073;;19747007;;10.2165/11318500-000000000-00000;;5637164;;10.1021/jm00307a041;;10.1016/j.bmcl.2003.12.063;;14980661;;10.1016/s1542-0124(12)70475-5;;22138447;;10.1016/j.bcp.2011.11.014;;12161441;;10.1074/jbc.m205932200;;10.1038/sj.bjp.0703520;;10952679;;pmc1572276;;14761197;;10.1021/jm0308848;;10.1107/s0108768100001683;;10877355;;2483534;;10.1248/cpb.37.1256;;11737931;;pmc64805;;10.1186/rr82;;18493878;;10.1007/s12016-008-8083-0;;19243943;;10.1016/j.bmcl.2009.02.016;;11104588;;10.1054/clnu.1999.0079;;15336384;;10.1016/j.ijpharm.2004.06.001;;4034636;;18117729;;10.1021/jo01154a013;;10.1248/cpb.38.2919;;10.1136/thx.2006.075887;;pmc2117234;;17600296;;10.1021/jo951790b;;22768130;;pmc3387224;;10.1371/journal.pone.0039809;;10.1021/jm990438d;;10841806;;10.1542/peds.2008-2059;;19171575;;10.1016/j.ijpharm.2011.06.027;;21726616;;12161441;;10.1074/jbc.m205932200;;1284534;;10.1002/humu.1380010304;;11354633;;10.1007/s004390100467;;10.1016/s1569-1993(09)60072-2;;10.1016/s1569-1993(09)60072-2;;10.1002/pauz.200890069;;18729285;;8410993;;10.1021/jm00071a010;;10.1016/j.jcf.2011.12.005;;22293084;;9191967;;10.1021/jm9700326;;pmc4622963;;10.1016/j.ijpharm.2015.08.101;;26341321;;10.1002/chin.201642262;;21658649;;10.1016/s1569-1993(11)60014-3;;10.1021/bi702209s;;18193900;;10.1021/jm00402a034;;3133478;;10.1016/0092-8674(90)90196-l;;2344617;;9002452;;10.1021/js9601896;;pmc4590721;;10.1016/j.apsb.2013.11.001;;26579360;;10.1016/j.ijpharm.2017.10.051;;29128423;;10.1016/0022-0248(96)00099-1;;8169784;;10.1002/jps.2600830212;;10.1002/jps.23031;;22213468;;10.1016/s0939-6411(03)00004-3;;12754010;;10.1002/jps.2600831008;;7884659;;10.1016/0378-5173(87)90115-3;;10.1002/jps.2600600902;;4935981;;10.1038/nrd1550;;15520815;;10.1016/s0065-7743(06)41030-7;;10.1002/jps.3030490417;;13854041;;16399359;;10.1016/s0076-6879(05)00020-0;;10430541;;10.1021/js980489i;;10.1081/ddc-120027506;;15000425;;16859407;;10.1517/17425255.2.4.591;;23209179;;pmc3543074;;10.1101/cshperspect.a009480;;10.1248/cpb.9.866,"Accurso, F. J. et al. (2009) “Final results of a 14- and 28-day study of VX-770 in subjects with CF” J. Cystic Fibrosis, vol. 8, Supplement 2, Abstracts of the 32nd European Cystic Fibrosis Conference, Jun. 10-13, 2009, Abstract 97, p. S25.;;American College of Chest Physicians (2004) Living Well With COPD: Chronic Bronchitis and Emphysema. Patient Education Guide. Northbrook, IL, USA; Product Code: 5032, 44 pages.;;Archimica (Oct. 2006) Coupling Agent ®T3P—The Water Scavenger. High-Performance Amide/Peptide Bond Formations, Dehydrations and Condensations. [online] Retrieved Apr. 11, 2011, from the Internet: http://www.archimica.com/PDF/ARCHIMICA_T3P_Brochure.pdf> (20 pages).;;Ashizawa, K. (2002) Polymorphism and Crystallization of the Pharmaceutical Drugs, pp. 273, 278, 305-317 (Japanese).;;Aulton, M.E. (Ed.) (2002) Pharmaceutics: The Science of Dosage Design. 2nd Ed. Churchill Livingston; pp. 304-321.;;Berge, S.M. et al. (1977) “Pharmaceutical Salts” J Pharmac Sci, 66(1):1-19.;;Bernstein, J. et al. (1995) “Patterns in Hydrogen Bonding: Functionality and Graph Set Analysis in Crystals” Angew Chem Int Ed Engl, 34:1555-1573.;;Bombeiri, C. et al. (1998) “Complete mutational screening of the CFTR gene in 120 patients with pulmonary disease” Human Genet, 103:718-722.;;Brittain, H. (Jul. 2001) “X-ray Diffraction III: Pharmaceutical Applications of X-ray Powder Diffraction” Spectroscopy, 16(7):14-18.;;Brittain, H.G. (Apr. 1997) “Spectral Methods for the Characterization of Polymorphs and Solvates” J Pharm Sci, 86(4):405-412.;;Brown, R.K. et al. (1954) “6-Aminoindole” J Am. Chem Soc, 76(20):5149-5150.;;Brown, R.K. et al. (1955) “Derivatives of Indole, 6-Amino-3-indoleacetic Acid” J Am Chem Soc, 77(14):3839-3842.;;Brown, R.K. et al. (1956) “Some Indole Derivatives Tested for Antitubercular Activity” J Org Chem, 21:261-262.;;Burvall, K.M. et al. (2002) “The tyrosine kinase inhibitor genistein increases basal cAMP and potentiates forskolin-induced cAMP accumulation in A549 human airway epithelial cells” Mol Cell Biol, 240:131-133.;;Byrn, S. et al. (1995) “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations” Pharmaceutical Research, 12(7):945-954.;;Cai, Z-W. et al. (2011) “Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis” Acta Pharmacologica Sinica, 32(6):693-701.;;Caira, M.R. (Jan. 1, 1998) “Crystalline Polymorphism of Organic Compounds” Topics in Chemistry, 198:163-208.;;Carta, A. et al. (2003) “Synthesis and Biological Evaluation of Triazolo[4,5-g]Quinolines, Imidazo[4,5-g]Quinolines and Pyriodo[2,3-g]Quinoxalines. Part II” Heterocycles, 60(4):833-842.;;Chemical Abstracts Service, ‘Registry’ File, RN 174311-74-1. STN Database [online]. Entry Date: Mar. 19, 1996, retrieved on Apr. 25, 2013.;;Chemical Abstracts Service, ‘Registry’ File, RN 325779-54-2. STN Database [online]. Entry Date: Mar. 6, 2001, retrieved on Jan. 28, 2016.;;Chemical Abstracts Service, ‘Registry’ File, RN 329691-97-6. STN Database [online]. Entry Date: Apr. 2, 2001, retrieved on Jan. 28, 2016.;;Chemical Abstracts Service, ‘Registry’ File, RN 329691-99-8. STN Database [online]. Entry Date: Apr. 2, 2001, retrieved on Jan. 28, 2016.;;Chemical Abstracts Service, ‘Registry’ File, RN 329692-01-5. STN Database [online]. Entry Date: Apr. 2, 2001, retrieved on Jan. 28, 2016.;;Chemical Abstracts Service, ‘Registry’ File, RN 329692-03-7. STN Database [online]. Entry Date: Apr. 2, 2001, retrieved on Jan. 28, 2016.;;Chemical Abstracts Service, ‘Registry’ File, RN 329692-05-9. STN Database [online]. Entry Date: Apr. 2, 2001, retrieved on Jan. 28, 2016.;;Chemical Abstracts Service, ‘Registry’ File, RN 329692-14-0. STN Database [online]. Entry Date: Apr. 2, 2001, retrieved on Jan. 28, 2016.;;Chemical Abstracts Service, ‘Registry’ File, RN 625115-91-5. STN Database [online]. Entry Date: Dec. 9, 2003, retrieved on Apr. 25, 2013.;;Chemical Abstracts Service, ‘Registry’ File, RN 629662-49-3. STN Database [online]. Entry Date: Dec. 22, 2003, retrieved on Jul. 24, 2015.;;Chemical Abstracts Service, ‘Registry’ File, RN 849644-14-0; STN Database SciFinder® [online]. Entry Date: Nov. 2, 2004, retrieved on Mar. 25, 2014.;;Clunes, M.T. et al. (2008) “Front-runners for pharmacotherapeutic correction of the airway ion transport defect in cystic fibrosis” Current Opinion in Pharmacology, 8(3):292-299.;;Collawn, J.F. et al. (2010) “Targets for cystic fibrosis therapy: proteomic analysis and correction of mutant cystic fibrosis transmembrane conductance regulator” Expert Review of Proteomics, 7(4):495-506.;;Cuthbert, A.W. (2010) “New horizons in the treatment of cystic fibrosis” Br J Pharmacol, 163:173-183.;;De Meeus, A. et al. (1998) “Genetic Findings in Congenital Bilateral Aplasia of Vas Deferens Patients and Identification of Six Novel Mutations” Human Mutation, Mutation in Brief, #138 [online]. DOI: 10.1002/(SICI)1098-1004(1998)11:6<480::AID-HUMU10>3.0.CO;2-Z, 10 pages. Final publication in vol. 11(6), p. 480.;;Dhar, T.G. M. et al. (2003) “3-Cyanoindole-based Inhibitors of Inosine Monophosphate Dehydrogenase: Synthesis and Initial Structure-Activity Relationships” Bioorg. Med. Chem. Lett., 13(20):3557-3560.;;Dif, F. et al. (2004) “Severe osteopenia in CFRT-null mice” Bone, 35:595-603.;;Dohmori, R. et al. (1976) “Synthetic Chemotherapeutic Agents. I. Synthesis of 2-Substituted Thiazolo[5,4-f]quinoline Derivatives” Chem Pharm Bull, 24:130-135.;;Eckford, P.D.W. et al. (2012) “Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Potentiator VX-770 (Ivacaftor) Opens the Defective Channel Gate of Mutant CFTR in a Phosphorylation-dependent but ATP-independent Manner” J Biol Chem, 287(44):36639-36649.;;Erlinger, S. (2011) “Molecular repair of a defective CFTR protein in cystic fibrosis” Clinics and Research in Hepatology and Gastroenterology, 35:254-256.;;Flume, P. A. et al. (2012) “Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation” Chest, 142:718-724.;;Galietta, L.J.V. et al. (2001) “Novel CFTR Chloride Channel Activators Identified by Screening of Combinatorial Libraries Based on Flavone and Benzoquinolizinium Lead Compounds” J Biol Chem, 276(23):19723-19728.;;Grant, D.J.W. (1999) “Theory and Origin of Polymorphism” in Polymorphism in Pharmaceutical Solids, H.G. Brittain, Ed.; Ch.1, pp. 1-10.;;Grohe, K. et al. (1987) “Synthese von 1-amino-4-chinolon-3-carbonsauren” Liebigs Annalen Der Chemie, 10:871-879.;;Guillory, J.K. (1999) “Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids” in Polymorphism in Pharmaceutical Solids. H.G. Brittain, Ed.; Ch.5, pp. 183-226.;;Guo, J-H. (Jun. 2004) “Lactose in Pharmaceutical Applications” Drug Delivery, vol. 4, No. 5 (7 pages).;;Hama, T. et al. (2003) “Palladium-Catalyzed α-Arylation of Esters and Amides under More Neutral Conditions” J Am Chem Soc, 125(37):11176-11177.;;Hancock, B.C. et al. (2000) “What is the True Solubility Advantage for Amorphous Pharmaceuticals?” Pharmaceutical Research, 17(4):397-404.;;Handbook for Preparing Crystal of Organic Compound—Principle and Know-how, Maruzen Co., Ltd Jul. 25, 2008, pp. 57-84 (Japanese).;;Hansen, K.T. et al. (Aug. 1991) “Carbamate ester prodrugs of dopaminergic compounds: synthesis, stability, and bioconversion” J Pharm Sci, 80(8):793-798.;;Haynes, R.K. et al. (1972) “Amine Oxidation and the Chemistry of Quinone Imines. Part I. 3-Methoxy-4-t-butylaniline” J Chem Soc, Perkins Trans, 1:396-408.;;Heilbron, I.M. et al. (1928) “The Intermolecular Condensation of Acetylmethylanthranilic Acid by Means of Phosphorus Pentachloride and the Formation of a Complex isoCyanine Dye” J Chem Soc, pp. 934-941.;;Hennequin, L.F. et al. (1999) “Design and Structure-Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors” J Med Chem, 42(26):5369-5389.;;Hester, J.B. et al. (1964) “Enzyme Inhibitory Activity of 3-(2-Aminobutyl)indole Derivatives” J Med Chem, 7(3):274-279.;;Hoffman, H.E. et al. (2005) “Allele-Specific Inhibitors of Protein Tyrosine Phosphatases” J Am Chem Soc, 127(9):2824-2825.;;Imanishi, T. et al. (1996) “Evidence that a Hybrid Molecule of Norfloxacin and Biphenylacetic Acid is a Potent Antagonist at the GABAA Receptor” Neuropharmacology, 35(9/10):1271-1277.;;International Patent Application No. PCTUS2005/022768, filed Jun. 24, 2005, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Jul. 25, 2006.;;International Patent Application No. PCT/US2006/048810, filed Dec. 21, 2006, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Jul. 26, 2007.;;International Patent Application No. PCT/US2006/048900, filed Dec. 21, 2006, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated May 25, 2007.;;International Patent Application No. PCT/US2006/049421, filed Dec. 28, 2006, by Vertex Pharmaceuticals, Inc.: International Search Report and Written Opinion, dated Sep. 25, 2007.;;International Patent Application No. PCT/US2007/068857, filed May 14, 2007, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Sep. 9, 2008.;;International Patent Application No. PCT/US2008/010728, filed Sep. 15, 2008, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Jul. 14, 2010.;;International Patent Application No. PCT/US2009/004629, filed Aug. 13, 2009, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Mar. 24, 2011.;;International Patent Application No. PCT/US2010/024609, filed Feb. 18, 2010, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Jun. 1, 2010.;;International Patent Application No. PCT/US2010/028062, filed Mar. 19, 2010, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated May 27, 2010.;;International Patent Application No. PCT/US2010/028069, filed Mar. 19, 2010, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Aug. 25, 2010.;;International Patent Application No. PCT/US2010/059920, filed Dec. 10, 2010, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Feb. 3, 2011.;;International Patent Application No. PCT/US2011/029276, filed Mar. 21, 2011, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated May 11, 2011.;;International Patent Application No. PCT/US2011/033687, filed Apr. 22, 2011, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Aug. 30, 2011.;;International Patent Application No. PCT/US2011/033689, filed Apr. 22, 2011, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Aug. 30, 2011.;;International Patent Application No. PCT/US2011/033693, filed Apr. 22, 2011, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Aug. 30, 2011.;;International Patent Application No. PCT/US2011/037457, filed May 20, 2011, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Jul. 13, 2011.;;International Patent Application No. PCT/US2011/049467, filed Aug. 26, 2011, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Apr. 2, 2012.;;International Patent Application No. PCT/US2012/034578, filed Apr. 20, 2012, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Mar. 21, 2013.;;International Patent Application No. PCT/US2012/063398, filed Nov. 2, 2012, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Jan. 23, 2013.;;International Patent Application No. PCT/US2013/028097, filed Feb. 27, 2013, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated May 10, 2013.;;International Patent Application No. PCT/US2013/044838, filed Jun. 7, 2013, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Aug. 5, 2013.;;International Patent Application No. PCT/US2015/054565, filed Oct. 7, 2015, by Vertex Pharmaceuticals Incorporated: International Search Report and Written Opinion, dated Jan. 11, 2016.;;International Search Report and Written Opinion dated Jan. 11, 2016, in International Patent Application No. PCT/US2015/054577.;;Irie, K. et al. (1995) “Synthesis of 6-Substituted Indolactams by Microbial Conversion” Tetrahedron, 51(22):6255-6266.;;Iskandarani, B. et al. (1993) “Simultaneous Optimization of Capsule and Tablet Formulation Using Response Surface Methodology” Drug Dev Industrial Pharmacy, 19(16):2089-2101.;;Ito, Y. et al. (1996) “Inhibition of GABAA Receptor Chloride Channel by Quinolones and Norfloxacin-Biphenylacetic Acid Hybrid Compounds” Neuropharmacology, 35(9/10):1263-1269.;;Jivraj, M. et al. (Feb. 2000) “An overview of the different excipients useful for the direct compression of tablets” PSTT, 3(2):58-63.;;Johannesson, J. et al. (Aug. 2012) “CFTR Regulates Early Pathogenesis of Chronic Obstructive Lung Disease in βENaC-Overexpressing Mice” PLoS ONE, 7(8):e44059 (11 pages).;;Johnson, H.E. et al. (1963) “Reactions of Indole. IV. The Synthesis of Some Aminoindoles” J Org Chem, 28(10):2794-2797.;;Jones, A.M. and J.M. Helm (2009) “Emerging Treatments in Cystic Fibrosis” Drugs, 69(14)1903-1910.;;Kaminsky, D. et al. (1968) “Quinolone Antibacterial Agents. Oxolinic Acid and Related Compounds” J Med Chem, 11(1):160-163.;;Kapranov, N.I. et al. (2004) “Cystic fibrosis: Recent Progress and Problems” Medical Genetics, 3(9):398-412, with English translation.;;Kurata, H. et al. (2004) “A novel class of apical sodium-dependent bile acid transporter inhibitors: the amphiphilic 4-oxo-1-phenyl-1,4-dihydroquinoline derivatives” Bioorg. Med. Chem. Lett., 14:1183-1186.;;Levine, M.H. et al. (2005) “CFTR-Regulated Chloride Transport at the Ocular Surface in Living Mice Measured by Potential Differences” Invest Ophthal Vis Sci, 46(4):1428-1434.;;Loo, T.W. et al. (2011) “Corrector-mediated rescue of misprocessed CFTR mutants can be reduced by the P-glycoprotein drug pump” Biochem Pharmacol, 83(3):345-354.;;Ma, T. et al. (2002) “High-affinity Activators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Conductance Identified by High-Throughput Screening” J. Biol. Chem., 277(40):37235-37241.;;Mall, M. et al. (2000) “Effect of genistein on native epithelial tissue from normal individuals and CF patients and on ion channels expressed in Xenopus oocytes” Br J Pharmacol, 130:1884-1892.;;Mandour, A.H. et al. (1999) “Aminolysis and Hydrolysis of Indolyl Oxazolones” Egyptian J Chem, 42(3):251-266.;;Marivingt-Mounir, C. et al. (Feb. 2004) “Synthesis, SAR, crystal structure, and biological evaluation of benzoquinoliziniums as activators of wild-type and mutant cystic fibrosis transmembrane conductance regulator channels” J Med Chem, 47(4):962-972.;;Mashkovskiy, M.D., Medicaments. Manual for Doctors. vol. 1, 14th Edition. Moscow: LLC “Novaya Volna”, 2001; p. 11.;;Miles, E.W. and R.S. Phillips (1985) “Photoinactivation and photoaffinity labeling of tryptophan synthase α2β2 complex by the product analogue 6-azido-L-tryptophan” Biochem, 24(17):4694-4703.;;Motherwell, W.D.S. et al. (2000) “Automated assignment of graph-set descriptors for crystallographically symmetric molecules” Acta Cryst, B56:466-473.;;Nishikawa, Y. et al. (1989) “Synthesis and Antiallergic Activity of N-[4-(4-Diphenylmethyl-1-piperazinyl)butyl]-1,4-dihydro-4-oxopyridine-3-carboxamides” Chem Pharm Bull, 37(5):1256-1259.;;Noone, P.G. et al. (2001) “‘CFTR-opathies’: disease phenotypes associated with cystic fibrosis transmembrane regulator gene mutations” Respiratory Research, 2(6):1-5.;;Nosova, E.V., et al. (2002) “Synthesis of new fluorinated derivatives of Quinolinecarboxylic acids” Chem. of Heter. Compounds, 38(8):922-928. Translated from: Khimiya Geterotsiklicheskikh Soedinenii, No. 8, pp. 1060-1066.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 13/290,491, dated Oct. 25, 2012.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 13/871,349, dated Apr. 17, 2015.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 13/871,349, dated Aug. 12, 2014.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 13/871,349, dated Oct. 13, 2015.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 13/887,839, dated Feb. 2, 2015.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 13/887,839, dated Jul. 7, 2014.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 13/887,839, dated Oct. 16, 2014.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 13/887,839, dated Sep. 30, 2015.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/031,360, dated Aug. 14, 2014.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/298,245, dated Jul. 21, 2015.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/298,245, dated Nov. 12, 2015.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/326,930, dated Aug. 14, 2015.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/326,930, dated Dec. 8, 2015.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/334,902, dated Feb. 18, 2016.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/334,902, dated Oct. 19, 2015.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/532,791, dated Jul. 24, 2015.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/532,791, dated Mar. 1, 2016.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/532,791, dated Nov. 6, 2015.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/567,475, dated Jan. 5, 2016.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/567,475, dated Sep. 21, 2015.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/579,098, dated Feb. 1, 2016.;;Notice of Allowability for U.S. Appl. No. 14/579,098, dated Apr. 18, 2016.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/579,098, dated May 12, 2016.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/656,043, dated Aug. 4, 2016.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/687286, dated Feb. 10, 2016.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/687,286, dated May 19, 2016.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/687,286, dated Sep. 28, 2016.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/877,914, dated Jul. 27, 2016.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/877,914, dated Nov. 14, 2016.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/925,804, dated May 17, 2016, Celia C. Chang.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 15/001,036, dated Feb. 10, 2017.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 15/073,591, dated Sep. 28, 2016, Celia C. Chang.;;Paranjape, S.M. et al. (2008) “Atypical Cystic fibrosis and CFTR-Related Diseases” Clinic Rev Allerg Immunol, 35(3):116-123.;;Paritala, H. et al. (2009) “Benzo(h)quinoline derivatives as G-quadruplex binding agents” Bioorg Med Chem Lett, 19(8):1584-1587.;;Pedemonte, N. et al. (2005) “Phenylglycine and sulfonamide correctors of defective ΔF508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating” Molecular Pharmacology, 67(5):1797-1807.;;Pedemonte, N. et al. (2005) “Small-molecule correctors of defective ΔF508-CFTR cellular processing identified by high-throughput screening” J Clin Invest, 115(9):2564-2571.;;Pencharz, P.D. and P.R. Durie (2000) “Pathogenesis of malnutrition in cystic fibrosis, and its treatment” Clin Nutr; 19(6):387-394.;;Pérez-Guille, B. et al. (2004) “Pharmacokinetics of a cephalone (CQ-M-EPCA) in rats after oral, intraduodenal and intravenous administration” Intl J Pharm, 282(1-2):87-94.;;Porst, H. and L. Kny (1985) “Zur Struktur der Abbauprodukte von Neostigminbromid (On the Structure of Degradation Products of Neostigmine bromide” Pharmazie, 40(5):325-328. German with English translation.;;Pubchem Compound No. CID 29877; Database Record No. 19962-04-0; Create Date Jul. 19, 2005 [online]. Retrieved from: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=29877; on Jan. 16, 2014 (4 pages).;;Roberts, R.M. (1949) “The reaction of diarylformamidines with ethyl malonate” J Org Chem, 14(2):277-284.;;Sashida, H. et al. (1990) “Studies of Seven Membered Heterocycles. XXXII. Synthesis of N-Unsubstituted 1H-1, 4-Benzodiazepines Stabilized by Intramolecular Hydrogen Bonding” Chem Pharm Bull, 38(11):2919-2925.;;Sen, A.B. et al. (1947) “Synthesis of Substituted Dinitrophenyl Ketones, and Phenylacetic Acids. Part I.” J. Indian Chem. Soc., 24:268-270.;;Sen, A.B., et al. (1948) “Synthesis of Substituted Dinitro Phenylketones and Phenylacetic Acids. Part III.” J Indian Chem Soc, 25:282-284.;;Sen, A.B., et al. (1948) “Synthesis of Substituted Dinitrophenyl Ketones and Phenylacetic Acids. Part IV.” J Indian Chem Soc, 25(8):403-404.;;Settimj, G. et al. (1988) “β-Carbolines as agonistic or antagonistic benzodiazepine receptor ligands. 1. Synthesis of some 5-, 6- and 7-amino derivatives of 3-methoxycarbonyl-β-carboline (β-CCM) and of 3-ethoxycarbonyl-β-carboline (β-CCE)” J Heterocyclic Chem, 25(5):1391-1397.;;Shead et al. (2007) “Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone” Thorax, 62:650-651.;;Shioji, Y. (Jan. 27, 2003) Manufacture Technology of Solid Preparation. CMC Publishing Co., Ltd.; pp. 9, 12, and 13 (Japanese).;;Showalter, H.D.H. et al. (1996) “Concise Syntheses of the Novel 1H-Pyrrolo[3,2-g]quinazoline Ring System and its [2,3-f] Angular Isomer” J Org Chem, 61(3):1155-1158.;;Silverman, R.B. (1992) The Organic Chemistry of Drug Design and Drug Action. San Diego, CA: Academic Press; pp. 5-51.;;Sloane, P.A. et al. (2010) “Translational readthrough of premature stop codons combined with CFTR potentiation: potential for combination CFTR therapy” Pediatric Pulmonology, 45(33):313, Abstract 264.;;Sloane, P.A. et al. (2012) “A Pharmacologic Approach to Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Smoking Related Lung Disease” PLoS ONE, 7(6):e39809 (13 pages).;;Srivastava, S.K. et al. (2000) “Quinolones: Novel Probes in Antifilarial Chemotheraphy” J Med Chem, 43(11):2275-2279.;;Thomson, S.A. et al. (2009) “Minitablets: New Modality to Deliver Medicines to Preschool-Aged Children” Pediatrics, 123:e235 (6 pages).;;Thomson Scientific, Database WPI, Accession No. 2001-425173; Week 200145.;;Tissen, C. et al. (2011) “Development of mini-tablets with 1 mm and 2 mm diameter” Int J Pharmaceutics, 416:164-170.;;Tonghui, M.A. et al. (2002) “High-affinity Activators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Conductance Identified by High-throughput Screening” J Biol Chem, 277(40):37235-37241.;;Tsui, L-C. (1992) “Mutations and Sequence Variations Detected in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene: A Report From the Cystic Fibrosis Genetic Analysis Consortium” Human Mutation, 1:197-203.;;Tzetis, M. et al. (2001) “CFTR gene mutations—including three novel nucleotide substitutions—and haplotype background in patients with asthma, disseminated bronchiectasis and chronic obstructive pulmonary disease” Hum Genet, 108:216-221.;;U.S. Department of Health and Human Services, Food and Drug Administration (Dec. 2002) Guidance for Industry. Food-Effect Bioavailability and Fed Bioequivalence Studies. (9 pages).;;U.S. Appl. No. 15/234,877, filed Aug. 11, 2016, by Hadida-Ruah et al.;;U.S. Appl. No. 15/342,999, filed Nov. 3, 2016, by Alargova et al.;;Van Es, T. et al. (2001) “N,1-Dialky1-7-(alkylamino)-4-(alkylimino)-1,4-dihydroquinoline-3-carboxamides and their 4-oxo derivatives: Synthesis and properties” S. Afr. J. Chem., 54:102-117.;;Van Es, T. et al. (2002) “1-alkyl-1,4-dihydro-4-iminoquinoline-3-carboxylic acids: Synthesis, Structure, and Properties” S. Afr. J. Chem., 55:13-33.;;Van Goor, F. et al. (2006) “Rescue of ΔF580-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules” Am J Physiol Lung Cell Mol Physiol, 290(6)L1117-L1130.;;Van Goor, F. et al. (2009) “Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770” J. Cystic Fibrosis, vol. 8, Supplement 2, Abstracts of the 32nd European Cystic Fibrosis Conference Jun. 10-13, 2009, Abstract 67, p. S17.;;Van Goor, F. et al. (2009) “Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VC-770” PNAS, 106(44):18825-18830.;;Vertex Pharmaceuticals, Inc. (May 17, 2006) “Vertex Pharmaceuticals Initiates Phase I Development for VX-770 in Cystic Fibrosis” [online]. Retrieved from: http://files.shareholder.com/downloads/VRTX/641260063x0x84745/fc8ddd6d-3713-48bb-b689-0444fc7ad623/VRTX_News_2006_5_17_General.pdf (2 pages).;;Vertex Pharmaceuticals, Inc. (Aug. 5, 2009) “Study of VX-770 in Cystic Fibrosis Subjects Age 12 and Older Homozygous for the F508del-CFTR Mutation” [online]. ClinicalTrials.gov, Identifier: NCT00953706. Retrieved from the Internet: http://clinicaltrials.gov/archive/NCT00953706/2009_08_05, on Jul. 10, 2013 (2 pages).;;Vertex Pharmaceuticals, Inc. (Jul. 12, 2010) “Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects Wth Cystic Fibrosis and the G551D Mutation” [online]. ClinicalTrials.gov, Identifier: NCT01161537. Retrieved from the Internet: hftp://clinicaltrials.gov/archive/NCT01262352/2010_12_16, on Jul. 9, 2013 (2 pages).;;Vertex Pharmaceuticals, Inc. (Oct. 31, 2011) “Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation” [online]. ClinicalTrials.gov, Identifier: NCT01225211. Retrieved from the Internet: http://clinicaltrials.gov/archive/NCT01225211/2011_10_31, on Jul. 10, 2013 (2 pages).;;Vertex Pharmaceuticals, Inc. (Jan. 2012) KALYDECO™(ivacaftor) Tablets. Patient Information. Reference ID: 3079771 (13 pages).;;Vestner, A. et al. (2008) “Neue Therapieansatze bei Cystischer Fibrose (New Therapy Approaches in Cystic Fibrosis” Pharmazie in unserer Zeit, 37(5): 354-355. doi:10.1002/pauz.200890069, with English translation.;;Wentland, M.P. et al. (1993) “Mammalian Topoisomerase II Inhibitory Activity of 1-Cyclopropy1-6,8-difluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-oxo-3-quinolinecarboxylic Acid and Related Derivatives” J Med Chem, 36:2801-2809.;;Yu, H. et al. (2010) “VX-770, an investigational CFTR potentiator, acts on multiple CFTR forms in vitro” Pediatric Pulmonology, 45(33):318-319, Abstract 280.;;Yu, H. et al. (2012) “Ivacaftor potentiation of multiple CFTR channels with gating mutations” J Cystic Fibrosis, 11(3):237-245.;;Akama, T. et al. (Jun. 1997) “Design and synthesis of potent antitumor 5,4′-diaminoflavone derivatives based on metabolic considerations” J Med Chem, 40(12):1894-1900.;;Alhalaweh, A. et al. (2015) “Physical stability of drugs after storage above and below the glass transition temperature: Relationship to glass-forming ability” Int J Pharm, 495(1):312-317.;;Baghel, S. et al. (2016) “Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs” J Pharm Sci, 105(9): 2527-2544.;;Bombieri et al., “Recommendations for the classification of diseases of CFTR-related disorders,” J. Cyst Fibros 10:2 S86-S102 (2011).;;Cheung, J. et al. (Feb. 2008) “Misfolding of the cystic fibrosis transmembrane conductance regulator and disease” Biochemistry, 47(6):1465-1473.;;Clemence, F. et al. (Jul. 1988) “4-Hydroxy-3-quinolinecarboxamides with antiarthritic and analgesic activities” J Med Chem, 31(7):1453-1462.;;Cystic Fibrosis Centre at the Hospital for Sick Children in Toronto, Cystic Fibrosis Mutation Database. [online] Retrieved from: http://www.genet.sickkids.on.ca/cftr/app, on Jul. 20, 2018.;;Dean, M. et al. (Jun. 1990) “Multiple mutations in highly conserved residues are found in mildly affected cystic fibrosis patients” Cell, 61:863-870.;;Hancock, B. and Zografi, G. (1997) “Characteristics and significance of the amorphous state in pharmaceutical systems” J Pharm Sci, 86(1):1-12.;;Huang, Y. and Dai, W. G. (2014) “Fundamental aspects of solid dispersion technology for poorly soluble drugs” Acta Pharm Sin B, 4(1):18-25.;;Jermain, S. V. et al. (2018) “Amorphous solid dispersions and nanocrystal technologies for poorly water-soluble drug delivery—An update” Int J Pharm, 535(1-2):379-392.;;Leusen, F.J.J. (1996) “Ab initio prediction of polymorphs” J Crystal Growth, 166:900-903.;;Martínez-Ohárriz, M.C. (1994) “Polymorphism of diflunisal: Isolation and solid-state characteristics of a new crystal form” J Pharm Sci, 83:174-177.;;Newman, A. et al. (2012) “Assessing the performance of amorphous solid dispersions” J Pharm Sci, 101(4):1355-1377.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/027,791, dated Jul. 31, 2015.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/687,286, dated Dec. 1, 2017.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/687,286, dated May 9, 2018.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 15/001,036, dated May 1, 2018.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 15/152,092, dated May 17, 2018.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 15/342,999, dated Apr. 17, 2018.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14/676,205, dated May 24, 2018.;;Patel, H. et al. (Aug. 2011) “New pharmaceutical excipients in solid dosage forms—A review” Intl J Pharm & Life Sci, 2(8):1006-1019.;;Rahman, Z. et al. (2013) “Tacrolimus Properties and Formulations: Potential Impact of Product Quality on Safety and Efficacy” 1-39.;;Swanepoel, E. et al. (2003) “Quality evaluation of generic drugs by dissolution test: changing the USP dissolution medium to distinguish between active and non-active mebendazole polymorphs” Eur J Pharma Biopharma, 55:345-349.;;Tao, T. (Dec. 31, 2011) “The progress and applications of flavoring and taste-masking technologies in new oral dosage forms” Shanghai Medical & Pharmaceutical Journal, 32(5):252-255 (Chinese; English Abstract on p. 252).;;U.S. Appl. No. 15/898,683, filed Feb. 19, 2018, by Frederick F. Van Goor, et al.;;U.S. Appl. No. 15/937,564, filed Mar. 27, 2018, by Frederick F. Van Goor, et al.;;U.S. Appl. No. 15/949,404, filed Apr. 10, 2018, by Sara Sabina Hadida Ruah.;;Wu, L-S. et al. (1994) “Investigation of moricizine hydrochloride polymorphs” J Pharm Sci, 83(10):1404-1406. Xu, W. et al. (Dec. 31, 2005) “Drug administration and dosage forms for children” Journal of Pharmaceutical Practice, 23(2):119-120 (Chinese).;;Xu, W. et al. (Dec. 31, 2005) “Drug administration and dosage forms for children” Journal of Pharmaceutical Practice, 23(2):119-120 (Chinese).;;Aulton, M.E. (Ed.) (2002) Pharmaceutics: The Science of Dosage Design. 2nd Ed. Churchill Livingston; p. 116.;;Aulton, M.E. (Ed.) (2007) Pharmaceutics: The Science of Dosage Design. 3rd Ed. Churchill Livingston; p. 340.;;Aungst, B.J. et al. (1987) “Prodrugs for improved oral nalbuphine bioavailability: inter-species differences in the disposition of nalbuphine and its acetylsalicylate and anthranilate esters” Int. J. Pharm., 38:199-209.;;Bauer, K.H. et al. (2007) Lehrbuch der Pharmazeutischen Technologie. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH; pp. 214-217, with English translation.;;Chiou, W.L. et al. (1971) “Pharmaceutical Applications of Solid Dispersion Systems” J Pharm Sci, 60(9):1281-1302.;;Gardner, C.R. et al. (2004) “Drugs as Materials: Valuing Physical Form in Drug Discovery” Nat Rev Drug Discov, 3:926-934.;;Hegde, S. et al. (2006) “To Market, to Market—2005” Annu Rep Med Chem, 41:439-477.;;Mullins, J.D. et al. (1960) “Some Pharmaceutical Properties of Novobiocin” J. Am. Pharm. Assoc. 49(4):245-248.;;Notice of Opposition for EP Patent Application No. 06848237.1, dated Nov. 11, 2017. et al.",ACTIVE
49,AU,A2,AU 2009/282419 A2,052-862-949-122-879,2011-03-31,2011,AU 2009/282419 A,2009-08-13,US 18334509 P;;US 8870408 P;;US 9009608 P;;US 18152709 P;;US 14616309 P;;US 8880108 P;;US 2009/0004629 W,2008-08-13,Pharmaceutical composition and administrations thereof,,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/052-862-949-122-879,Patent Application,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K47/32,,0,0,,,,ACTIVE
50,EA,B1,EA 021706 B1,175-686-570-633-99X,2015-08-31,2015,EA 201170330 A,2009-08-13,US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P;;US 2009/0004629 W,2008-08-13,"TABLET COMPRISING A SOLID DISPERSION OF N-[2,4-BIS-(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE-3-CABOXAMIDE, AND ADMINISTRATION THEREOF","The present invention relates to pharmacology, in particular, to a tablet comprising a solid dispersion of N-[2,4-bis-(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide and to a method of administration thereof. The claimed tablet is characterised by well solubility and high stability.",VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/175-686-570-633-99X,Granted Patent,no,1,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K47/32,,0,0,,,,ACTIVE
51,AU,A1,AU 2009/282419 A1,047-677-350-965-022,2010-02-18,2010,AU 2009/282419 A,2009-08-13,US 18334509 P;;US 8870408 P;;US 9009608 P;;US 18152709 P;;US 14616309 P;;US 8880108 P;;US 2009/0004629 W,2008-08-13,Pharmaceutical composition and administrations thereof,,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/047-677-350-965-022,Patent Application,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K47/32,,0,0,,,,ACTIVE
52,DK,T3,DK 2328618 T3,058-955-351-792-617,2018-02-19,2018,DK 09789125 T,2009-08-13,US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P;;US 2009/0004629 W,2008-08-13,"FARMACEUTISK SAMMENSÆTNING AF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLIN-3-CARBOXAMID OG ADMINISTRATION DERAF",,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/058-955-351-792-617,Granted Patent,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K47/32;;A61K9/16;;A61K9/20;;A61K9/28;;A61K31/47,,0,0,,,,ACTIVE
53,JP,A,JP 2014111656 A,017-509-058-121-18X,2014-06-19,2014,JP 2014048523 A,2014-03-12,US 14616309 P;;US 8880108 P;;US 18334509 P;;US 8870408 P;;US 9009608 P;;US 18152709 P,2008-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF,"PROBLEM TO BE SOLVED: To provide a pharmaceutical composition and administrations thereof.SOLUTION: The present invention relates to a pharmaceutical composition containing a solid dispersion of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (compound 1), methods for manufacturing the pharmaceutical composition of the present invention, and methods for administering the pharmaceutical composition of the present invention. The pharmaceutical composition of the present invention also includes one or more of the following excipients: a filler, a disintegrant, a glidant, a lubricant, a binder, and a surfactant. In one embodiment, the present invention provides the pharmaceutical composition comprising the solid dispersion of an amorphous compound 1, wherein the solid dispersion comprises about 25 mg of the amorphous compound 1.",VERTEX PHARMA,WILLIAM ROWE;;PATRICIA HURTER;;CHRISTOPHER YOUNG;;KIRK DINEHART;;MARINUS JACOBUS VERWIJS;;KIRK OVERHOFF;;PETER D J GROOTENHUIS;;MARTYN BOTFIELD;;ALFREDO GROSSI,,https://lens.org/017-509-058-121-18X,Patent Application,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K47/32;;A61K9/20;;A61K9/28;;A61K9/44;;A61K31/47;;A61K47/02;;A61K47/04;;A61K47/10;;A61K47/12;;A61K47/14;;A61K47/20;;A61K47/26;;A61K47/34;;A61K47/36;;A61K47/38;;A61K47/44;;A61P1/10;;A61P1/16;;A61P1/18;;A61P3/00;;A61P3/06;;A61P3/10;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P35/00;;A61P37/08,,0,0,,,,DISCONTINUED
54,LT,T,LT 2328618 T,099-823-144-648-017,2018-03-26,2018,LT 09789125 T,2009-08-13,US 14616309 P;;US 8880108 P;;US 18334509 P;;US 8870408 P;;US 9009608 P;;US 18152709 P;;US 2009/0004629 W,2008-08-13,"PHARMACEUTICAL COMPOSITION OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4- OXOQUINOLINE-3-CARBOXAMIDE AND ADMINISTRATION THEREOF",,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/099-823-144-648-017,Unknown,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K47/32;;A61K9/16;;A61K9/20;;A61K9/28;;A61K31/47,,0,0,,,,PENDING
55,SI,T1,SI 3345625 T1,121-925-399-408-472,2021-04-30,2021,SI 200932107 T,2009-08-13,US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P;;EP 17204189 A,2008-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF,,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/121-925-399-408-472,Granted Patent,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K31/00;;A61K9/00,,0,0,,,,ACTIVE
56,AU,A1,AU 2016/216569 A1,142-825-602-679-766,2016-09-01,2016,AU 2016/216569 A,2016-08-16,AU 2016/216569 A;;AU 2009/282419 A;;US 18334509 P;;US 8870408 P;;US 9009608 P;;US 18152709 P;;US 14616309 P;;US 8880108 P;;US 2009/0004629 W,2008-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF,"The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3 carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.",VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO;;VERWIJS MARINUS JACOBUS,,https://lens.org/142-825-602-679-766,Patent Application,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K47/32,,0,0,,,,INACTIVE
57,AU,B2,AU 2016/216569 B2,005-603-673-245-104,2018-01-25,2018,AU 2016/216569 A,2016-08-16,AU 2016/216569 A;;AU 2009/282419 A;;US 18334509 P;;US 8870408 P;;US 9009608 P;;US 18152709 P;;US 14616309 P;;US 8880108 P;;US 2009/0004629 W,2008-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF,"The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3 carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.",VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO;;VERWIJS MARINUS JACOBUS,,https://lens.org/005-603-673-245-104,Granted Patent,no,1,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K47/32,,0,0,,,,INACTIVE
58,RS,B1,RS 61408 B1,044-466-191-419-120,2021-03-31,2021,RS P20210129 A,2009-08-13,US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P;;EP 17204189 A,2008-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF,,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/044-466-191-419-120,Granted Patent,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K9/16;;A61K9/20;;A61K9/28;;A61K31/47,,0,0,,,,ACTIVE
59,KR,A,KR 20220057663 A,061-252-339-848-830,2022-05-09,2022,KR 20227014317 A,2009-08-13,US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P;;KR 20197037948 A;;US 2009/0004629 W,2008-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF,"본 발명은 N-[2,4-비스(1,1-디메틸에틸)-5-히드록시페닐]-1,4-디히드로-4-옥소퀴놀린-3-카르복스아미드의 고체 분산물을 포함하는 제약 조성물, 본 발명의 제약 조성물의 제조 방법 및 본 발명의 제약 조성물의 투여 방법에 관한 것이다.",VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/061-252-339-848-830,Patent Application,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K9/16;;A61K9/20;;A61K31/47;;A61P43/00,,0,0,,,,DISCONTINUED
60,WO,A2,WO 2010/019239 A2,119-073-573-184-525,2010-02-18,2010,US 2009/0004629 W,2009-08-13,US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P,2008-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF,"The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline- 3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.",VERTEX PHARMA;;ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/119-073-573-184-525,Patent Application,yes,0,115,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K47/32,,0,0,,,,PENDING
61,KR,A,KR 20110042356 A,190-319-209-157-223,2011-04-26,2011,KR 20117005734 A,2009-08-13,US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P,2008-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF,,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/190-319-209-157-223,Patent Application,no,0,2,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K31/47;;A61K9/28;;A61K47/30;;A61K47/48,,0,0,,,,DISCONTINUED
62,US,A1,US 2023/0210839 A1,002-574-710-012-416,2023-07-06,2023,US 202218091476 A,2022-12-30,US 202218091476 A;;US 202016842480 A;;US 201615253636 A;;US 201314135323 A;;US 58306609 A;;US 18334509 P;;US 18152709 P;;US 14616309 P;;US 9009608 P;;US 8880108 P;;US 8870408 P,2008-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF,"The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.",VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,VERTEX PHARMACEUTICALS INCORPORATED (2010-07-28),https://lens.org/002-574-710-012-416,Patent Application,yes,4,0,1,98,0,A61K31/47;;A61K31/44;;A61K31/4709;;A61K9/2077;;A61K9/1635;;A61K9/1652;;A61K9/1617;;A61K9/2054;;A61K9/2018;;A61K9/1635;;A61K9/282;;A61K9/1652;;A61K31/44;;A61K9/2054;;A61K31/47;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2027;;A61K9/284;;A61K9/0053;;A61K9/28;;A61K9/2866;;A61K9/2813;;A61K9/2826;;A61K9/2853,A61K31/47;;A61K9/00;;A61K9/20;;A61K9/28,,2,2,013-411-306-711-576;;009-142-861-977-050,10.1016/s1569-1993(01)00003-0;;15463806;;12124395;;10.1074/jbc.m206121200,"Vankeerberghen et al. (J. of Cystic Fibrosis, 2002, 1, 13-29);;Dérand et al. (J. of Biol. Chem., 2002, 277(39), 35999-36004)",PENDING
63,ES,T3,ES 2857152 T3,161-970-826-778-851,2021-09-28,2021,ES 17204189 T,2009-08-13,US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P,2008-08-13,Composición farmacéutica y administraciones de la misma,"Una composición farmacéutica que comprende una dispersión sólida, en donde la dispersión sólida comprende: a) 80% en peso de N-[2,4-Bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolin-3-carboxamida (Compuesto 1) amorfa o sustancialmente amorfa por peso de la dispersión, en donde el Compuesto 1 sustancialmente amorfo comprende menos del 15% de Compuesto 1 cristalino, b) 19,5% en peso de succinato de acetato de hidroxipropilmetilcelulosa (HPMCAS) o copolímero de vinilpirrolidona/acetato de vinilo (PVP/VA) por peso de la dispersión, y c) 0,5% en peso de lauril sulfato de sodio (SLS) por peso de la dispersión.",VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO,,https://lens.org/161-970-826-778-851,Granted Patent,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K9/16;;A61K9/20;;A61K9/28;;A61K31/47,,0,0,,,,ACTIVE
64,EP,B1,EP 3345625 B1,167-384-844-493-098,2020-12-09,2020,EP 17204189 A,2009-08-13,US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P;;EP 09789125 A;;US 2009/0004629 W,2008-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF,,VERTEX PHARMA,GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO;;ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK,,https://lens.org/167-384-844-493-098,Granted Patent,yes,3,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K9/16;;A61K9/20;;A61K9/28;;A61K31/47,,5,4,013-424-688-679-155;;013-424-688-679-155;;074-225-865-565-732;;017-391-007-464-253,22383668;;pmc3435140;;10.1378/chest.11-2672;;22383668;;pmc3435140;;10.1378/chest.11-2672;;18061887;;10.1016/j.drudis.2007.09.005;;20977292;;10.1517/17425247.2010.528199,"FLUME PATRICK A., THEODORE G. LIOU, DRUCY S. BOROWITZ, HAIHONG LI , KARL YEN, CLAUDIA L. ORDOÑEZ, DAVID E. GELLER: ""Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation"", CHEST, vol. 142, no. 3, 2012, pages 718 - 724, XP055842618, DOI: 10.1378/chest.11-2672;;ANONYMOUS: ""Food's journey through the digestive system"", SCIENCE LEARNING HUB, 23 April 2014 (2014-04-23), pages 1 - 7, XP055843614;;FLUME P. A., LIOU T. G., BOROWITZ D. S., LI H., YEN K., ORDONEZ C. L., GELLER D. E.: ""Ivacaftor in Subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation"", CHEST, vol. 142, no. 3, 2012, pages 718 - 724, XP055842618;;VASCONCELOS T., SARMENTO B., COSTA P.: ""Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs"", DRUG DISCOVERY TODAY, vol. 12, no. 23, 2007, pages 1068 - 1075, XP022370275;;Expert opinion- Isidoro CARABALLO",INACTIVE
65,ZA,B,ZA 201101097 B,086-043-614-514-015,2012-05-30,2012,ZA 201101097 A,2011-02-10,US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P;;US 2009/0004629 W,2008-08-13,"PHARMACEUTICAL COMPOSITION OF N-[2,4-BIS (1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXAMIDE AND ADMINISTRATION THEREOF",,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN C;;GROSSI ALFREDO,,https://lens.org/086-043-614-514-015,Granted Patent,no,0,0,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K/,,0,0,,,,ACTIVE
66,HU,T2,HU E042437 T2,116-052-304-613-676,2019-07-29,2019,HU E10708442 A,2010-02-18,US 2009/0004629 W;;US 58306609 A,2009-08-13,"Tablet formulation of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide for use in the treatment of cystic fibrosis",,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS;;OVERHOFF KIRK;;GROOTENHUIS PETER;;BOTFIELD MARTYN;;GROSSI ALFREDO;;ZLOKARNIK GREGOR;;VAN GOOR FREDRICK F,,https://lens.org/116-052-304-613-676,Amended Patent,no,0,0,33,98,0,A61K9/1635;;A61K9/1652;;A61K9/282;;A61K31/44;;A61K9/2054;;A61K31/47;;A61P11/00;;A61P11/08;;A61P19/00;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/00;;A61P43/00;;A61K31/47;;A61K9/14;;A61K9/1635;;A61K9/282;;A61K9/1652;;A61K31/44;;A61K9/2054;;A61K31/47;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2027;;A61K9/284;;A61K9/0053;;A61K9/28,A61K9/14;;A61K31/44;;A61K31/47;;A61K45/06;;A61P19/00;;A61P19/10;;A61P43/00,,0,0,,,,PENDING
67,LT,T,LT 2464337 T,179-842-359-857-83X,2019-05-10,2019,LT 10708442 T,2010-02-18,US 2009/0004629 W;;US 58306609 A;;US 2010/0024609 W,2009-08-13,"Tablet formulation of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide for use in the treatment of cystic fibrosis",,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER;;DINEHART KIRK;;VERWIJS MARINUS;;OVERHOFF KIRK;;GROOTENHUIS PETER;;BOTFIELD MARTYN;;GROSSI ALFREDO;;ZLOKARNIK GREGOR;;VAN GOOR FREDRICK F,,https://lens.org/179-842-359-857-83X,Unknown,no,0,0,33,98,0,A61K9/1635;;A61K9/1652;;A61K9/282;;A61K31/44;;A61K9/2054;;A61K31/47;;A61P11/00;;A61P11/08;;A61P19/00;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/00;;A61P43/00;;A61K31/47;;A61K9/14;;A61K9/1635;;A61K9/282;;A61K9/1652;;A61K31/44;;A61K9/2054;;A61K31/47;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2027;;A61K9/284;;A61K9/0053;;A61K9/28,A61K9/14;;A61K31/44;;A61K31/47;;A61K45/06;;A61P19/00;;A61P19/10;;A61P43/00,,0,0,,,,PENDING
68,PL,T3,PL 2464337 T3,128-425-503-036-474,2019-07-31,2019,PL 10708442 T,2010-02-18,US 58306609 A;;EP 10708442 A;;US 2009/0004629 W;;US 2010/0024609 W,2009-08-13,"Tablet formulation of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide for use in the treatment of cystic fibrosis",,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER R;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO;;ZLOKARNIK GREGOR;;VAN GOOR FREDRICK F,,https://lens.org/128-425-503-036-474,Patent Application,no,0,0,33,98,0,A61K9/1635;;A61K9/1652;;A61K9/282;;A61K31/44;;A61K9/2054;;A61K31/47;;A61P11/00;;A61P11/08;;A61P19/00;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/00;;A61P43/00;;A61K31/47;;A61K9/14;;A61K9/1635;;A61K9/282;;A61K9/1652;;A61K31/44;;A61K9/2054;;A61K31/47;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2027;;A61K9/284;;A61K9/0053;;A61K9/28,A61K9/14;;A61K31/44;;A61K31/47;;A61K45/06;;A61P19/00;;A61P19/10;;A61P43/00,,0,0,,,,PENDING
69,US,A1,US 2010/0256184 A1,035-492-359-265-27X,2010-10-07,2010,US 70835910 A,2010-02-18,US 70835910 A;;US 58306609 A;;US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P,2008-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF,"The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.",VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER R;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO;;ZLOKARNIK GREGOR;;VAN GOOR FREDRICK F,VERTEX PHARMACEUTICALS INCORPORATED (2010-02-18),https://lens.org/035-492-359-265-27X,Patent Application,yes,4,139,3,98,0,A61K9/146;;A61K9/1652;;A61K9/2018;;A61K9/2054;;A61K9/282;;A61K9/2866;;A61K47/38;;A61P11/00;;A61P19/08;;A61P19/10;;A61P37/00;;A61K47/38;;A61K9/2018;;A61K9/2866;;A61K9/282;;A61K9/1652;;A61K9/146;;A61K9/2054;;A61K31/47,A61K31/47;;A61P11/00;;A61P19/08;;A61P19/10,514/312,3,0,,,"Excipient Update and ""Pharmaceutics: The science of Dosage form design"", 1988.;;American College of Chest Physician, 2004;;Jian-Hwa, Drug Development and Delivery, Vol. 4, No. 5 (June 2004).",DISCONTINUED
70,PT,T,PT 2464337 T,074-484-652-372-992,2019-05-03,2019,PT 10708442 T,2010-02-18,US 58306609 A;;US 2009/0004629 W,2009-08-13,"TABLET FORMULATION OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXAMIDE FOR USE IN THE TREATMENT OF CYSTIC FIBROSIS",,VERTEX PHARMA,WILLIAM ROWE;;PATRICIA HURTER;;CHRISTOPHER R YOUNG;;KIRK DINEHART;;MARINUS JACOBUS VERWIJS;;KIRK OVERHOFF;;PETER D J GROOTENHUIS;;MARTYN BOTFIELD;;ALFREDO GROSSI;;GREGOR ZLOKARNIK;;FREDRICK F VAN GOOR,,https://lens.org/074-484-652-372-992,Patent Application,no,0,0,33,98,0,A61K9/1635;;A61K9/1652;;A61K9/282;;A61K31/44;;A61K9/2054;;A61K31/47;;A61P11/00;;A61P11/08;;A61P19/00;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/00;;A61P43/00;;A61K31/47;;A61K9/14;;A61K9/1635;;A61K9/282;;A61K9/1652;;A61K31/44;;A61K9/2054;;A61K31/47;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2027;;A61K9/284;;A61K9/0053;;A61K9/28,A61K9/14;;A61K31/44;;A61K31/47;;A61K45/06;;A61P19/00;;A61P19/10;;A61P43/00,,0,0,,,,PENDING
71,RS,B1,RS 58604 B1,075-300-700-178-893,2019-05-31,2019,RS P20190432 A,2010-02-18,US 58306609 A;;US 2009/0004629 W;;US 2010/0024609 W;;EP 10708442 A,2009-08-13,"TABLET FORMULATION OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXAMIDE FOR USE IN THE TREATMENT OF CYSTIC FIBROSIS",,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER R;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO;;ZLOKARNIK GREGOR;;VAN GOOR FREDRICK F,,https://lens.org/075-300-700-178-893,Granted Patent,no,0,0,33,98,0,A61K9/1635;;A61K9/1652;;A61K9/282;;A61K31/44;;A61K9/2054;;A61K31/47;;A61P11/00;;A61P11/08;;A61P19/00;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/00;;A61P43/00;;A61K31/47;;A61K9/14;;A61K9/1635;;A61K9/282;;A61K9/1652;;A61K31/44;;A61K9/2054;;A61K31/47;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2027;;A61K9/284;;A61K9/0053;;A61K9/28,A61K9/14;;A61K31/44;;A61K31/47;;A61K45/06;;A61P19/00;;A61P19/10;;A61P43/00,,0,0,,,,ACTIVE
72,DK,T3,DK 2464337 T3,135-095-197-071-080,2019-04-23,2019,DK 10708442 T,2010-02-18,US 58306609 A;;US 2010/0024609 W;;US 2009/0004629 W,2009-08-13,"Tabletformulering af N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid til anvendelse til behandling af cystisk fibrose",,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER R;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO;;ZLOKARNIK GREGOR;;VAN GOOR FREDRICK F,,https://lens.org/135-095-197-071-080,Granted Patent,no,0,0,33,98,0,A61K9/1635;;A61K9/1652;;A61K9/282;;A61K31/44;;A61K9/2054;;A61K31/47;;A61P11/00;;A61P11/08;;A61P19/00;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/00;;A61P43/00;;A61K31/47;;A61K9/14;;A61K9/1635;;A61K9/282;;A61K9/1652;;A61K31/44;;A61K9/2054;;A61K31/47;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2027;;A61K9/284;;A61K9/0053;;A61K9/28,A61K9/14;;A61K31/44;;A61K31/47;;A61K45/06;;A61P19/00;;A61P19/10;;A61P43/00,,0,0,,,,ACTIVE
73,NZ,A,NZ 597823 A,139-784-178-771-398,2014-05-30,2014,NZ 59782310 A,2010-02-18,US 2010/0024609 W;;US 58306609 A;;US 2009/0004629 W,2009-08-13,Pharmaceutical composition and administrations thereof,"597823 Disclosed herein are pharmaceutical compositions comprising a solid dispersion of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (compound 1) for use treating or lessening the severity of cystic fibrosis in a patient, and method of manufacturing said compositions. In a preferred embodiment the patient possesses a cystic fibrosis transmembrane receptor (CFTR) with a ΔF508 mutation or G551D mutation on both alleles.",VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER R;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO;;ZLOKARNIK GREGOR;;VAN GOOR FREDRICK F,,https://lens.org/139-784-178-771-398,Patent Application,no,0,0,33,98,0,A61K9/1635;;A61K9/1652;;A61K9/282;;A61K31/44;;A61K9/2054;;A61K31/47;;A61P11/00;;A61P11/08;;A61P19/00;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/00;;A61P43/00;;A61K31/47;;A61K9/14;;A61K9/1635;;A61K9/282;;A61K9/1652;;A61K31/44;;A61K9/2054;;A61K31/47;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2027;;A61K9/284;;A61K9/0053;;A61K9/28,A61K9/14;;A61K31/47;;A61P19/00;;A61P19/10;;A61P43/00,,0,0,,,,PENDING
74,CA,A1,CA 2769695 A1,167-041-144-131-040,2011-02-17,2011,CA 2769695 A,2010-02-18,US 2009/0004629 W;;US 58306609 A;;US 2010/0024609 W,2009-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF,"The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis( 1, 1 -dimethylethyl)-5-hydroxyphenyl]- 1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.",VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER R;;DINEHART KIRK;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO;;ZLOKARNIK GREGOR;;VAN GOOR FREDRICK F;;VERWIJS MARINUS JACOBUS,,https://lens.org/167-041-144-131-040,Patent Application,no,0,12,33,98,0,A61K9/1635;;A61K9/1652;;A61K9/282;;A61K31/44;;A61K9/2054;;A61K31/47;;A61P11/00;;A61P11/08;;A61P19/00;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/00;;A61P43/00;;A61K31/47;;A61K9/14;;A61K9/1635;;A61K9/282;;A61K9/1652;;A61K31/44;;A61K9/2054;;A61K31/47;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2027;;A61K9/284;;A61K9/0053;;A61K9/28,A61K9/14;;A61K31/47;;A61P19/00;;A61P19/10;;A61P43/00,,0,0,,,,DISCONTINUED
75,AU,A1,AU 2010/282986 A1,062-130-937-367-376,2012-02-16,2012,AU 2010/282986 A,2010-02-18,US 58306609 A;;US 2009/0004629 W;;US 2010/0024609 W,2009-08-13,Pharmaceutical composition and administrations thereof,"The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis( 1, 1 -dimethylethyl)-5-hydroxyphenyl]- 1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.",VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER R;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO;;ZLOKARNIK GREGOR;;VAN GOOR FREDRICK F,,https://lens.org/062-130-937-367-376,Patent Application,no,0,0,33,98,0,A61K9/1635;;A61K9/1652;;A61K9/282;;A61K31/44;;A61K9/2054;;A61K31/47;;A61P11/00;;A61P11/08;;A61P19/00;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/00;;A61P43/00;;A61K31/47;;A61K9/14;;A61K9/1635;;A61K9/282;;A61K9/1652;;A61K31/44;;A61K9/2054;;A61K31/47;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2027;;A61K9/284;;A61K9/0053;;A61K9/28,A61K9/14;;A61K31/47;;A61P19/00;;A61P19/10;;A61P43/00,,0,0,,,,DISCONTINUED
76,CY,T1,CY 1121572 T1,150-390-515-138-064,2020-05-29,2020,CY 191100385 T,2019-04-08,US 2009/0004629 W;;US 58306609 A;;US 2010/0024609 W,2009-08-13,"ΣΚΕΥΑΣΜΑ ΔΙΣΚΙΟΥ ΤΟΥ Ν-[2,4-ΔΙΣ(1,1-ΔΙΜΕΘΥΛΑΙΘΥΛ)-5-ΥΔΡΟΞΥΦΑΙΝΥΛ]-1,4-ΔΙΥΔΡΟ-4-ΟΞΟΚΙΝΟΛΙΝΟ-3-ΚΑΡΒΟΞΑΜΙΔΙΟΥ ΓΙΑ ΧΡΗΣΗ ΣΤΗ ΘΕΡΑΠΕΙΑ ΚΥΣΤΙΚΗΣ ΙΝΩΣΗΣ","Η παρούσα εφεύρεση αφορά σε φαρμακευτικές συνθέσεις που περιλαμβάνουν διασπορά στερεού του Ν-[2,4-Δις(1,1-διμεθυλαιθυλ)-5-υδροξυφαινυλ]-1,4-διυδρο-4-οξοκινολινο-3 καρβοξαμιδίου, μεθόδους βιομηχανικής κατασκευής φαρμακευτικών συνθέσεων της παρούσας εφεύρεσης και μεθόδους χορήγησης φαρμακευτικών συνθέσεων της παρούσας εφεύρεσης.",VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER R;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO;;ZLOKARNIK GREGOR;;VAN GOOR FREDRICK F,,https://lens.org/150-390-515-138-064,Granted Patent,no,0,0,33,98,0,A61K9/1635;;A61K9/1652;;A61K9/282;;A61K31/44;;A61K9/2054;;A61K31/47;;A61P11/00;;A61P11/08;;A61P19/00;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/00;;A61P43/00;;A61K31/47;;A61K9/14;;A61K9/1635;;A61K9/282;;A61K9/1652;;A61K31/44;;A61K9/2054;;A61K31/47;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2027;;A61K9/284;;A61K9/0053;;A61K9/28,A61K9/14;;A61K31/44;;A61K31/47;;A61K45/06;;A61P19/00;;A61P19/10;;A61P43/00,,0,0,,,,ACTIVE
77,US,A1,US 2014/0315948 A1,016-386-262-809-586,2014-10-23,2014,US 201414318325 A,2014-06-27,US 201414318325 A;;US 201213418927 A;;US 70835910 A;;US 58306609 A;;US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P,2008-08-13,Pharmaceutical Composition and Administrations Thereof,"The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.",VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER R;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO;;ZLOKARNIK GREGOR;;VAN GOOR FREDRICK F,VERTEX PHARMACEUTICALS INCORPORATED (2010-02-18),https://lens.org/016-386-262-809-586,Patent Application,yes,1,43,3,98,0,A61K9/146;;A61K9/1652;;A61K9/2018;;A61K9/2054;;A61K9/282;;A61K9/2866;;A61K47/38;;A61P11/00;;A61P19/08;;A61P19/10;;A61P37/00;;A61K47/38;;A61K9/2018;;A61K9/2866;;A61K9/282;;A61K9/1652;;A61K9/146;;A61K9/2054;;A61K31/47,A61K31/47;;A61K47/38,514/312,1,1,074-925-352-415-074,10.1136/thx.2006.075887;;pmc2117234;;17600296,"Shead et al, Thorax 2007;62:650-651.",DISCONTINUED
78,MX,A,MX 2012001939 A,186-044-255-535-50X,2012-03-29,2012,MX 2012001939 A,2010-02-18,US 2009/0004629 W;;US 58306609 A;;US 2010/0024609 W,2009-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF.,"The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis( 1, 1 -dimethylethyl)-5-hydroxyphenyl]- 1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.",VERTEX PHARMA,GROOTENHUIS PETER D J;;ZLOKARNIK GREGOR;;HURTER PATRICIA;;GROSSI ALFREDO;;ROWE WILLIAM;;DINEHART KIRK;;OVERHOFF KIRK;;BOTFIELD MARTYN;;VERWIJS MARINUS JACOBUS;;GOOR FREDRICK F VAN;;YOUNG CHRISTOPHER R,,https://lens.org/186-044-255-535-50X,Patent Application,no,0,0,33,98,0,A61K9/1635;;A61K9/1652;;A61K9/282;;A61K31/44;;A61K9/2054;;A61K31/47;;A61P11/00;;A61P11/08;;A61P19/00;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/00;;A61P43/00;;A61K31/47;;A61K9/14;;A61K9/1635;;A61K9/282;;A61K9/1652;;A61K31/44;;A61K9/2054;;A61K31/47;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2027;;A61K9/284;;A61K9/0053;;A61K9/28,A61K47/32;;A61K9/14;;A61K31/47;;A61P19/00;;A61P19/10;;A61P43/00,,0,0,,,,PENDING
79,US,A1,US 2012/0220625 A1,010-484-920-867-624,2012-08-30,2012,US 201213370540 A,2012-02-10,US 2009/0004629 W;;US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P,2008-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF,"The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.",ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER R;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO;;ZLOKARNIK GREGOR;;VAN GOOR FREDRICK F;;VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER R;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO;;ZLOKARNIK GREGOR;;VAN GOOR FREDRICK F,VERTEX PHARMACEUTICALS INCORPORATED (2010-02-18),https://lens.org/010-484-920-867-624,Patent Application,yes,3,69,60,98,0,A61K9/1635;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K31/47;;A61P1/10;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/12;;A61P15/08;;A61P19/04;;A61P19/08;;A61P19/10;;A61P21/02;;A61P25/00;;A61P25/16;;A61P25/22;;A61P25/28;;A61P27/02;;A61P3/00;;A61P35/00;;A61P3/06;;A61P37/08;;A61P5/06;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/00;;A61P7/10;;A61P3/10;;A61K31/00;;A61K9/1652;;A61K9/2054;;A61K9/282;;A61K9/1635;;A61K31/47;;A61P7/10;;A61P11/16;;A61P35/00;;A61P15/08;;A61P19/08;;A61P5/14;;A61P5/18;;A61P11/02;;A61P11/04;;A61P25/22;;A61P27/02;;A61P21/02;;A61P11/06;;A61P19/10;;A61P3/06;;A61P1/16;;A61P3/00;;A61P37/08;;A61P13/02;;A61P1/10;;A61P1/18;;A61P3/10;;A61P7/00;;A61P11/00;;A61P25/00;;A61P13/12;;A61P19/04;;A61P5/50;;A61P25/28;;A61P5/06;;A61P25/16;;A61K31/47;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K9/2027;;A61P43/00;;A61K9/1652;;A61K9/1635;;A61K9/2054;;A61K31/47;;A61K9/282,A61K31/47;;A61P11/00;;A61P19/08;;A61P19/10,514/312,5,4,076-110-890-744-671;;074-925-352-415-074;;039-754-651-973-866;;077-598-286-712-276,15336594;;10.1016/j.bone.2004.05.021;;10.1136/thx.2006.075887;;pmc2117234;;17600296;;10664574;;10.1016/s1461-5347(99)00237-0;;10.3109/03639049309069343,"Dif et al (Severe osteopenia in CFTR-null mice. Bone, 2004; 35:595- 603);;Shead et al (""Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone. Thorax, 2007; 62:650-651).;;Jivraj et al (""An overview of the different excipients useful for the directcompression of tablets."" PSTT 2000; 3(2):58-63);;Iskandarani et al (""Simulataneous optimization of capsule and tablet formulation using response surface methodology."" Drug Development and Industrial Pharmacy, 1993; 19(16): 2089-2101);;Kaydeco(TM) (ivacaftor) Tablets - Prescribing information Jan - 2012",DISCONTINUED
80,EP,A1,EP 2464337 A1,046-122-006-845-990,2012-06-20,2012,EP 10708442 A,2010-02-18,US 2009/0004629 W;;US 58306609 A;;US 2010/0024609 W,2009-08-13,"Tablet formulation of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide for use in the treatment of cystic fibrosis",,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER R;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO;;ZLOKARNIK GREGOR;;VAN GOOR FREDRICK F,VERTEX PHARMACEUTICALS INC. (2014-02-26);;VERTEX PHARMACEUTICALS INCORPORATED (2014-08-27),https://lens.org/046-122-006-845-990,Patent Application,yes,0,0,33,98,0,A61K9/1635;;A61K9/1652;;A61K9/282;;A61K31/44;;A61K9/2054;;A61K31/47;;A61P11/00;;A61P11/08;;A61P19/00;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/00;;A61P43/00;;A61K31/47;;A61K9/14;;A61K9/1635;;A61K9/282;;A61K9/1652;;A61K31/44;;A61K9/2054;;A61K31/47;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2027;;A61K9/284;;A61K9/0053;;A61K9/28,A61K9/14;;A61K31/47;;A61P19/00;;A61P19/10;;A61P43/00,,0,0,,,,ACTIVE
81,BR,A2,BR 112012008082 A2,074-415-302-102-096,2016-03-01,2016,BR 112012008082 A,2010-02-18,US 2010/0024609 W;;US 2009/0004629 W;;US 58306609 A,2009-08-13,composição farmacêutica e adminstrações da mesma,,VERTEX PHARMA,GROSSI ALFREDO;;YOUNG CHRISTOPHER R;;GOOR FREDRICK F VAN;;ZLOKARNIK GREGOR;;DINEHART KIRK;;OVERHOFF KIRK;;VERWIJS MARINUS JACOBUS;;BOTFIELD MARTYN;;HURTER PATRICIA;;GROOTENHUIS PETER D J;;ROWE WILLIAM,,https://lens.org/074-415-302-102-096,Patent Application,no,0,0,33,98,0,A61K9/1635;;A61K9/1652;;A61K9/282;;A61K31/44;;A61K9/2054;;A61K31/47;;A61P11/00;;A61P11/08;;A61P19/00;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/00;;A61P43/00;;A61K31/47;;A61K9/14;;A61K9/1635;;A61K9/282;;A61K9/1652;;A61K31/44;;A61K9/2054;;A61K31/47;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2027;;A61K9/284;;A61K9/0053;;A61K9/28,A61K9/14;;A61K31/47;;A61P19/00;;A61P19/10;;A61P43/00,,0,0,,,,DISCONTINUED
82,US,A1,US 2012/0258983 A1,081-150-736-660-530,2012-10-11,2012,US 201213418927 A,2012-03-13,US 201213418927 A;;US 70835910 A;;US 58306609 A;;US 8870408 P;;US 8880108 P;;US 9009608 P;;US 14616309 P;;US 18152709 P;;US 18334509 P,2008-08-13,Pharmaceutical Composition and Administrations Thereof,"The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.",ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER R;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO;;ZLOKARNIK GREGOR;;VAN GOOR FREDRICK F;;VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER R;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO;;ZLOKARNIK GREGOR;;VAN GOOR FREDRICK F,VERTEX PHARMACEUTICALS INCORPORATED (2010-02-18),https://lens.org/081-150-736-660-530,Patent Application,yes,1,61,3,98,0,A61K9/146;;A61K9/1652;;A61K9/2018;;A61K9/2054;;A61K9/282;;A61K9/2866;;A61K47/38;;A61P11/00;;A61P19/08;;A61P19/10;;A61P37/00;;A61K47/38;;A61K9/2018;;A61K9/2866;;A61K9/282;;A61K9/1652;;A61K9/146;;A61K9/2054;;A61K31/47,A61K31/47;;A61P11/00;;A61P19/08;;A61P19/10;;A61P37/00,514/312,2,1,033-336-884-979-126,11104588;;10.1054/clnu.1999.0079,"Food and Drug Administration, U.S. Department of Health and Human Services, Guidance for Industry, December, 2002.;;Pencharz et al, Clinical Nutrition (2000) 19(6): 387-394.",DISCONTINUED
83,CN,A,CN 102497859 A,109-650-852-229-997,2012-06-13,2012,CN 201080041507 A,2010-02-18,US 2010/0024609 W;;US 58306609 A;;US 2009/0004629 W,2009-08-13,Pharmaceutical composition and administrations thereof,"The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis( 1, 1 -dimethylethyl)-5-hydroxyphenyl]- 1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.",VERTEX PHARMACEUTICALS INCORPORATE,WILLIAM ROWE;;PATRICIA HURTER;;YOUNG CHRISTOPHER R;;KIRK DINEHART;;JACOBUS VERWIJS MARINUS;;KIRK OVERHOFF;;GROOTENHUIS PETER D J;;MARTYN BOTFIELD;;ALFREDO GROSSI;;GREGOR ZLOKARNIK;;GOOR FREDRICK F VAN,,https://lens.org/109-650-852-229-997,Patent Application,no,1,0,33,98,0,A61K9/1635;;A61K9/1652;;A61K9/282;;A61K31/44;;A61K9/2054;;A61K31/47;;A61P11/00;;A61P11/08;;A61P19/00;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/00;;A61P43/00;;A61K31/47;;A61K9/14;;A61K9/1635;;A61K9/282;;A61K9/1652;;A61K31/44;;A61K9/2054;;A61K31/47;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2027;;A61K9/284;;A61K9/0053;;A61K9/28,A61K9/14;;A61K31/47;;A61P19/00;;A61P19/10;;A61P43/00,,0,0,,,,DISCONTINUED
84,ME,B,ME 03356 B,091-982-748-237-259,2019-10-20,2019,ME P10119 A,2010-02-18,US 2009/0004629 W;;US 58306609 A;;EP 10708442 A;;US 2010/0024609 W,2009-08-13,"N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXAMIDE FOR USE IN THE TREATMENT OF CYSTIC FIBROSIS",,VERTEX PHARMA,VAN GOOR FREDRICK F;;ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER R;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;BOTFIELD MARTYN;;GROSSI ALFREDO;;ZLOKARNIK GREGOR;;OVERHOFF KIRK;;GROOTENHUIS PETER D J,,https://lens.org/091-982-748-237-259,Granted Patent,no,0,0,33,98,0,A61K9/1635;;A61K9/1652;;A61K9/282;;A61K31/44;;A61K9/2054;;A61K31/47;;A61P11/00;;A61P11/08;;A61P19/00;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/00;;A61P43/00;;A61K31/47;;A61K9/14;;A61K9/1635;;A61K9/282;;A61K9/1652;;A61K31/44;;A61K9/2054;;A61K31/47;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2027;;A61K9/284;;A61K9/0053;;A61K9/28,A61K31/44;;A61K9/14;;A61K31/47;;A61K45/06;;A61P19/00;;A61P19/10;;A61P43/00,,0,0,,,,ACTIVE
85,WO,A1,WO 2011/019413 A1,101-264-539-525-750,2011-02-17,2011,US 2010/0024609 W,2010-02-18,US 2009/0004629 W;;US 58306609 A,2009-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF,"The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis( 1, 1 -dimethylethyl)-5-hydroxyphenyl]- 1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.",VERTEX PHARMA;;ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER R;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO;;ZLOKARNIK GREGOR;;VAN GOOR FREDRICK F,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER R;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO;;ZLOKARNIK GREGOR;;VAN GOOR FREDRICK F,,https://lens.org/101-264-539-525-750,Patent Application,yes,5,79,33,98,0,A61K9/1635;;A61K9/1652;;A61K9/282;;A61K31/44;;A61K9/2054;;A61K31/47;;A61P11/00;;A61P11/08;;A61P19/00;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/00;;A61P43/00;;A61K31/47;;A61K9/14;;A61K9/1635;;A61K9/282;;A61K9/1652;;A61K31/44;;A61K9/2054;;A61K31/47;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2027;;A61K9/284;;A61K9/0053;;A61K9/28,A61K9/14;;A61K31/47;;A61P19/00;;A61P19/10;;A61P43/00,,16,14,035-502-640-621-586;;106-691-342-610-490;;057-817-191-735-303;;020-889-257-201-858;;011-275-553-053-877;;164-990-444-435-834;;027-495-322-764-618;;062-658-814-888-724;;115-252-470-991-090;;147-561-926-460-635;;059-603-579-320-605;;139-606-967-003-103;;009-491-011-950-586;;007-364-858-655-289,10.1016/s1569-1993(09)60101-6;;10.1016/s1569-1993(09)60072-2;;10.1016/j.coph.2008.04.006;;pmc2517236;;18468487;;10.1002/pauz.200890069;;18729285;;1699127;;10.1038/347382a0;;2475911;;10.1126/science.2475911;;1695717;;10.1038/346366a0;;10.1016/0092-8674(90)90196-l;;2344617;;10.1126/science.2570460;;2570460;;2236053;;pmc54973;;10.1073/pnas.87.21.8447;;10.1096/fasebj.4.10.2197151;;2197151;;10.1038/354526a0;;1722027;;7539001;;10.1074/jbc.270.21.12347;;10.1002/jps.2600660104;;833720,"ON BEHALF OF THE VX-770 STUDY INVESTIGATORS ET AL: ""Final results of a 14- and 28-day study of VX-770 in subjects with CF"", JOURNAL OF CYSTIC FIBROSIS, ELSEVIER, vol. 8, 1 June 2009 (2009-06-01), pages S25, XP026192272, ISSN: 1569-1993, [retrieved on 20090601];;VAN GOOR F ET AL: ""Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770"", JOURNAL OF CYSTIC FIBROSIS, ELSEVIER, vol. 8, 1 June 2009 (2009-06-01), pages S17, XP026192243, ISSN: 1569-1993, [retrieved on 20090601];;CLUNES M T ET AL: ""Front-runners for pharmacotherapeutic correction of the airway ion transport defect in cystic fibrosis"", CURRENT OPINION IN PHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS, NL LNKD- DOI:10.1016/J.COPH.2008.04.006, vol. 8, no. 3, 1 June 2008 (2008-06-01), pages 292 - 299, XP022711870, ISSN: 1471-4892, [retrieved on 20080528];;A. VESTNER ET AL.: ""Neue Therapieansätze bei Cystischer Fibrose"", PHARMAZIE UNSERER ZEIT, vol. 37, no. 5, 2008, pages 354 - 355, XP002581329;;ANONYMOUS: ""Vertex Pharmaceuticals initiates Phase I development for VX-770 in Cystic Fibrosis"", INTERNET CITATION, 17 May 2006 (2006-05-17), pages 1 - 2, XP002528469, Retrieved from the Internet <URL:http://files.shareholder.com/downloads/VRTX/641260063x0x84745/fc8ddd6 d-3713-48bb-b689-0444fc7ad623/VRTX_News_2006_5_17_General.pdf> [retrieved on 20090518];;GREGORY, R. J. ET AL., NATURE, vol. 347, 1990, pages 382 - 386;;RICH, D. P. ET AL., NATURE, vol. 347, 1990, pages 358 - 362;;RIORDAN, J. R. ET AL., SCIENCE, vol. 245, 1989, pages 1066 - 1073;;CUTTING, G. R. ET AL., NATURE, vol. 346, 1990, pages 366 - 369;;DEAN, M. ET AL., CELL, vol. 61, 1990, pages 863 - 870;;KEREM, B-S. ET AL., SCIENCE, vol. 245, 1989, pages 1073 - 1080;;KEREM, B-S ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 8447 - 8451;;QUINTON, P. M., FASEB J., vol. 4, 1990, pages 2709 - 2727;;DALEMANS ET AL., NATURE LOND., vol. 354, 1991, pages 526 - 528;;FOSKETT, J. CELL. BIOCHEM., vol. 270, 1995, pages 12347 - 50;;J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19",PENDING
86,KR,A,KR 20120061875 A,142-341-561-083-34X,2012-06-13,2012,KR 20127006386 A,2010-02-18,US 58306609 A;;US 2010/0024609 W;;US 2009/0004629 W,2009-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF,,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER R;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO;;ZLOKARNIK GREGOR;;VAN GOOR FREDRICK F,,https://lens.org/142-341-561-083-34X,Patent Application,no,0,0,33,98,0,A61K9/1635;;A61K9/1652;;A61K9/282;;A61K31/44;;A61K9/2054;;A61K31/47;;A61P11/00;;A61P11/08;;A61P19/00;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/00;;A61P43/00;;A61K31/47;;A61K9/14;;A61K9/1635;;A61K9/282;;A61K9/1652;;A61K31/44;;A61K9/2054;;A61K31/47;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2027;;A61K9/284;;A61K9/0053;;A61K9/28,A61K9/14;;A61P19/00;;A61P19/10,,0,0,,,,DISCONTINUED
87,ES,T3,ES 2718273 T3,146-489-057-717-290,2019-06-28,2019,ES 10708442 T,2010-02-18,US 2009/0004629 W;;US 58306609 A;;US 2010/0024609 W,2009-08-13,"Formulación de tableta de N-[2,4-bis(1,1-dimetiletilo)-5-hidroxifenilo]-1,4-dihidro-4-oxoquinolina-3-carboxamida para uso en el tratamiento de fibrosis quística",,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER R;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO;;ZLOKARNIK GREGOR;;VAN GOOR FREDRICK F,,https://lens.org/146-489-057-717-290,Granted Patent,no,0,0,33,98,0,A61K9/1635;;A61K9/1652;;A61K9/282;;A61K31/44;;A61K9/2054;;A61K31/47;;A61P11/00;;A61P11/08;;A61P19/00;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/00;;A61P43/00;;A61K31/47;;A61K9/14;;A61K9/1635;;A61K9/282;;A61K9/1652;;A61K31/44;;A61K9/2054;;A61K31/47;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2027;;A61K9/284;;A61K9/0053;;A61K9/28,A61K9/14;;A61K31/44;;A61K31/47;;A61K45/06;;A61P19/00;;A61P19/10;;A61P43/00,,0,0,,,,ACTIVE
88,HR,T1,HR P20190660 T1,023-519-821-446-081,2019-05-31,2019,HR P20190660 T,2019-04-05,US 58306609 A;;US 2009/0004629 W;;EP 10708442 A;;US 2010/0024609 W,2009-08-13,"TABLET FORMULATION OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXAMIDE FOR USE IN THE THE TREATMENT OF CYSTIC FIBROSIS",,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER R;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO;;ZLOKARNIK GREGOR;;VAN GOOR FREDRICK F,,https://lens.org/023-519-821-446-081,Granted Patent,no,0,0,33,98,0,A61K9/1635;;A61K9/1652;;A61K9/282;;A61K31/44;;A61K9/2054;;A61K31/47;;A61P11/00;;A61P11/08;;A61P19/00;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/00;;A61P43/00;;A61K31/47;;A61K9/14;;A61K9/1635;;A61K9/282;;A61K9/1652;;A61K31/44;;A61K9/2054;;A61K31/47;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2027;;A61K9/284;;A61K9/0053;;A61K9/28,A61K9/14;;A61K31/44;;A61K31/47;;A61K45/06;;A61P19/00;;A61P19/10;;A61P43/00,,0,0,,,,ACTIVE
89,SG,A1,SG 178337 A1,061-188-119-098-35X,2012-03-29,2012,SG 2012009080 A,2010-02-18,US 58306609 A;;US 2009/0004629 W;;US 2010/0024609 W,2009-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF,"The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis( 1, 1 -dimethylethyl)-5-hydroxyphenyl]- 1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.",VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER R;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO;;ZLOKARNIK GREGOR;;VAN GOOR FREDRICK F,,https://lens.org/061-188-119-098-35X,Patent Application,no,0,0,33,98,0,A61K9/1635;;A61K9/1652;;A61K9/282;;A61K31/44;;A61K9/2054;;A61K31/47;;A61P11/00;;A61P11/08;;A61P19/00;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/00;;A61P43/00;;A61K31/47;;A61K9/14;;A61K9/1635;;A61K9/282;;A61K9/1652;;A61K31/44;;A61K9/2054;;A61K31/47;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2027;;A61K9/284;;A61K9/0053;;A61K9/28,,,0,0,,,,PENDING
90,ZA,B,ZA 201200722 B,087-323-558-936-880,2013-05-29,2013,ZA 201200722 A,2012-01-30,US 58306609 A;;US 2009/0004629 W;;US 2010/0024609 W,2009-08-13,PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF,,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER R;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO;;ZLOKARNIK GREGOR;;VAN GOOR FREDRICK F,,https://lens.org/087-323-558-936-880,Granted Patent,no,0,0,33,98,0,A61K9/1635;;A61K9/1652;;A61K9/282;;A61K31/44;;A61K9/2054;;A61K31/47;;A61P11/00;;A61P11/08;;A61P19/00;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/00;;A61P43/00;;A61K31/47;;A61K9/14;;A61K9/1635;;A61K9/282;;A61K9/1652;;A61K31/44;;A61K9/2054;;A61K31/47;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2027;;A61K9/284;;A61K9/0053;;A61K9/28,A61P/;;A61K/,,0,0,,,,ACTIVE
91,EP,B1,EP 2464337 B1,194-648-423-579-497,2019-01-09,2019,EP 10708442 A,2010-02-18,US 2009/0004629 W;;US 58306609 A;;US 2010/0024609 W,2009-08-13,"Tablet formulation of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide for use in the treatment of cystic fibrosis",,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER R;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO;;ZLOKARNIK GREGOR;;VAN GOOR FREDRICK F,VERTEX PHARMACEUTICALS INC. (2014-02-26);;VERTEX PHARMACEUTICALS INCORPORATED (2014-08-27),https://lens.org/194-648-423-579-497,Granted Patent,yes,5,0,33,98,0,A61K9/1635;;A61K9/1652;;A61K9/282;;A61K31/44;;A61K9/2054;;A61K31/47;;A61P11/00;;A61P11/08;;A61P19/00;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/00;;A61P43/00;;A61K31/47;;A61K9/14;;A61K9/1635;;A61K9/282;;A61K9/1652;;A61K31/44;;A61K9/2054;;A61K31/47;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2027;;A61K9/284;;A61K9/0053;;A61K9/28,A61K9/14;;A61K31/44;;A61K31/47;;A61K45/06;;A61P19/00;;A61P19/10;;A61P43/00,,6,0,,,"""Vertex Pharmaceuticals Initiates Phase 3 Registration Program for VX-770, an Oral CFTR Potentiator Targeting the Defective Protein Responsible for Cystic Fibrosis"", VERTEX PRESS RELEASE, 27 May 2009 (2009-05-27), XP002528469;;DATABASE chemspider ""Lumacaftor"", XP055651669, Database accession no. 17611836;;""Vertex Pharmaceuticals Initiates Phase 2 Development for CFTR Corrector VX-809 in Patients with Cystic Fibrosis"", VERTEX PRESS RELEASE, 25 March 2009 (2009-03-25), XP055651674;;""Pharmaceutics - The science of dosage form design"", EDT. M E AULTON, 1998, Churchill Livingston, pages 304 - 305, XP055651697;;""Food's journey through the digestive system"", 1 October 2019 (2019-10-01), XP055651703, Retrieved from the Internet <URL:https://www.sciencelearn.org.nz/resources/1849-food-s-journey-through-the-digestive- system>;;RAYMOND C ROWE ET AL.: ""Handbook of pharmaceutical excipients"", 31 July 2009, article ""cellelose microcrystaline"", pages: 129-133,185-188,206-208,376-378,404,651 - 653, XP055651710",ACTIVE
92,SI,T1,SI 2464337 T1,195-976-488-125-575,2019-05-31,2019,SI 201031871 T,2010-02-18,US 2009/0004629 W;;US 58306609 A;;US 2010/0024609 W;;EP 10708442 A,2009-08-13,"Tablet formulation of N-(2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide for use in the treatment of cystic fibrosis",,VERTEX PHARMA,ROWE WILLIAM;;HURTER PATRICIA;;YOUNG CHRISTOPHER R;;DINEHART KIRK;;VERWIJS MARINUS JACOBUS;;OVERHOFF KIRK;;GROOTENHUIS PETER D J;;BOTFIELD MARTYN;;GROSSI ALFREDO;;ZLOKARNIK GREGOR;;VAN GOOR FREDRICK F,,https://lens.org/195-976-488-125-575,Granted Patent,no,0,0,33,98,0,A61K9/1635;;A61K9/1652;;A61K9/282;;A61K31/44;;A61K9/2054;;A61K31/47;;A61P11/00;;A61P11/08;;A61P19/00;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/00;;A61P43/00;;A61K31/47;;A61K9/14;;A61K9/1635;;A61K9/282;;A61K9/1652;;A61K31/44;;A61K9/2054;;A61K31/47;;A61K9/2009;;A61K9/2013;;A61K9/2018;;A61K9/2027;;A61K9/284;;A61K9/0053;;A61K9/28,A61K9/00;;A61K31/00;;A61K45/00;;A61P19/00;;A61P43/00,,0,0,,,,ACTIVE
